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LL-NAMEL-NAME (N-nitro-L-arginine methyl ester), like
L-NMMA, is a structural analogue of L-arginine and
competes with L-arginine for NO-synthase, which
uses L-arginine as a substrate for the formation of
NO. L-NMMA and L-NAME are very effective
NO-synthesis inhibitors, both in vitro and in vivo.
▶NO Synthase
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▶β-Lactam antibiotics are bicyclic or monocyclic
azetidinone ring-containing compounds ( Fig. 1). They
kill bacteria by preventing the assembly of (4 –3)
peptidoglycans. These covalently closed net-like poly-
mers form the matrix of the cell wall by which the
bacteria can divide and multiply, despite their high
internal osmotic pressure.
Mechanism of Action
▶Peptidoglycans of the (4 –3) and (3–3) types ( Fig. 2)
are comprised of glycan chains made of alternating
β-1,4-linked N-acetylglucosamine and N-acetylmura-
mic acid residues [1]. The D -lactyl groups on carbon C3
of the muramic acids are substituted by L-alanyl- γ - D -
glutamyl- L -diaminoacyl- D -alanine stem tetrapeptides.
In the (4 –3) peptidoglycans, peptides borne by adjacent
glycan chains are cross-linked through direct linkages
or cross bridges (comprising one or several interveningamino acid residues) that extend from the D-alanine
residue at position 4 of a stem peptide to the ω-amino
group at position 3 of another stem peptide. Lipid II
( Fig. 3) is the immediate biosynthetic precursor.
A disaccharide bearing an L-alanyl- γ - D-glutamyl- L-
diaminoacyl- D -alanyl- D-alanine stem pentapeptide (the
diamino acid residue of which can be either free, i.e.,
unsubstituted, or substituted by one or several amino
acid residues, i.e., branched) is exposed on the outer face
of the plasma membrane, linked to a C55 -undecaprenyl
via a pyrophosphate. From this precursor, the formation
of polymeric (4–3) peptidoglycans relies on glycosyl
transferases ensuring glycan chain elongation and
acyl transferases ensuring peptide cross linking. Acyl
transferases of the SXXK superfamily (▶ SXXK Acyl
Transferases, also called DD-transpeptidases, with X
denoting a variable amino acid residue) are implicated in
cross linking and they exhibit a specific bar code in the
form of three motifs, SXXK, SXN (or analogue) and
KTG (or analogue), occurring at equivalent places and
roughly with the same spacing along the polypeptide
chains [2]. As a result of the polypeptide folding, the
motifs are brought close to each other at the immediate
boundary of the catalytic centre between an all-α domain
and an α/β domain. SXXK acyl transferases identify
N-acyl-D-alanyl-D-alanine sequences as carbonyl donors,
produce a N-acyl-D-alanyl moiety linked as an ester
to the serine residue of the invariant SXXK motif
and transfer the peptidyl moiety onto an amino group
(transpeptidation) or a water molecule (carboxypeptida-
tion). SXXK acyl transferases identify penicillin (used
as a generic term for β-lactam antibiotics) as a suicide
carbonyl donor. Because the serine-ester linked peni-
cilloyl enzyme that SXXK acyl transferases produce is
rather stable, they are immobilized, at least for a long
time, in the form of penicillin-binding proteins, in short
PBPs. The inactivation reaction can be written
where E-OH is the enzyme, with –OH the hydroxyl
group of its active-site serine residue. Kinetically, the
interaction is described by a 3-step model
b-Lactam Antibiotics. Figure 1 Bicyclic (penams, 3-cephems, oxacephems and carbapenems) and monocyclic
(aztreonam) β-lactam antibiotics. Rupture of the scissile amide bond of the azetidinone ring (arrow) by the SXXK acyl
transferases implicated in (4–3) peptidoglycan synthesis results in the formation of long-lived, serine-linked acyl ester
derivatives. The inactivated enzymes behave as penicillin-binding proteins or PBPs.
680 b-Lactam Antibioticswhere I is the β-lactam, P(s) the product(s) resulting
from the very slow decay of the EI* penicilloyl enzyme.
K is the dissociation constant of the EI, a non-covalent
complex and k2 and k3 first-order rate constants. In all
cases, k3 has been found to be very small and K is
generally large so that the sensitivity of a PBP to a
β-lactam is best characterized by the k2/K ratio [3]. This
ratio varies from 1,000,000 M −1s− 1 for the most
sensitive PBP to less than 1 for the most resistant.
Lethal Target Proteins
A constellation of genes code for PBPs of varying
amino acid sequences and functionalities. PBPs occur
as free-standing polypeptides and as protein fusions.
This combinatorial system of structural modules results
in a large increase in diversity.▶SXXK PBP fusions of classes A and B are the lethal
ta rg et s o f β-lactam antibiotics. The PBP fusions of class A
are comprised of an SXXK acyl transferase module of
class A, linked to the carboxy end of a glycosyl
transferase module having its own five motif-bar code,
itself linked to the carboxy end of a membrane anchor [2].
They convert the disaccharide–pentapeptide units borne
by lipid II precursormolecules into nascent polymeric (4–
3) peptidoglycans. Glycan chain elongation is catalysed
by the transglycosylase module. Peptide cross linking
between elongated glycanchains is then carried out by the
associated SXXK acyl transferase module. The PBP
fusions of class B are comprised of an SXXK acyl
transferase module of class B, bound to the carboxy end
of a linker module having its own three-motif bar code,
itself linked to a membrane anchor. They are components
ofmorphogenetic apparatus that controls wall expansion,
ensures cell-shape maintenance and carries out septum
formation. Likely, the linker modules ensure that the
b-Lactam Antibiotics. Figure 2 (4–3) Peptidoglycan (the synthesis of which is susceptible to β-lactam antibiotics)
and (3–3) peptidoglycan (the synthesis of which is resistant to antibiotics) in Escherichia coli and Mycobacterium
tuberculosis. G:N-acetylglucosamine. M:N-acetylmuramic acid (i.e.,N-acetylglucosamine with a D-lactyl substituent
on carbon C3). A2pm: meso-diaminopimelic acid. In E. coli and M. tuberculosis, the stem peptides are unbranched.
COX: COOH (in E. coli) or CONH2 (in M. tuberculosis).
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Lassociated SXXK acyl transferase modules are positioned
in an active conformation within the morphogenetic
apparatus where they need to be. Binding of β-lactam
antibiotics to the SXXK acyl transferase modules of the
PBP fusions leads to the formation of Henri–Michaelis
complexes that exhibit ligand- and enzyme-specific hy-
drogen bonding networks. Es ch er ic hi a c ol i is killed in a
number of ways; via cell lysis as a result of the selective
inactivation of the class A PBP1a and PBP1b (which
can substitute for each other) by cephaloridine and
cefsulodin; via transformation of the cells into
round bodies as a result of the selective inactivation of
t he c el l- cy cl e s ub cl as s B 2 P B P 2 b y m ec il li na m a nd
thienamycin; via cell filamentation as a result of the
selective inactivation of the cell-cycle subclass B3 PBP3
by mezlocillin, cefaperazone, cefotaxime, cefuroxime,
cephalothin and aztreonam; or via different combinations
of these morphological alterations by ampicillin, benzyl-
penicillin, carbenicillin and cefoxitin.
b-Lactamase-Mediated Resistance
▶SXXK free-standing PBPs are peptidoglycan-hydro-
lases of one kind or another. Loss of these auxilliary
cell-cycle proteins causes varying morphological aber-
rations, but is not fatal at least in the laboratory
environment. Similarly, conversion of free-standing
PBPs into β-lactam antibiotic-hydrolysing enzymes,
with loss of peptidase activity and conservation of the
polypeptide fold, gives rise to the SXXK β- lactamases .
There are three classes of SXXK β-lactamases A, C and
D, which are easily distinguished on the basis of their
primary structures, although the tertiary structures areclearly similar and also related to those of the acyl
transferase modules of PBPs. In particular, in addition
to the characteristic SXXK, motifs reminiscent of the
bar code SXN and KTG groups are found in nearly
superimposable positions. The catalytic pathway of
β-lactamases follows the 3-step model shown above but
with good substrates, the k3 value can be higher than
1000 s −1 [4].
The class A enzymes have Mr values around 30,000.
Their substrate specificities are quite variable and a
large number of enzymes have emerged in response to
the selective pressure exerted by the sometimes abusive
utilization of antibiotics. Some of these “new enzymes”
are variants of previously known enzymes, with only a
limited number of mutations (1–4) but a significantly
broadened substrate spectrum while others exhibit
significantly different sequences. The first category is
exemplified by the numerous TEM variants whose
activity can be extended to third and fourth generation
cephalosporins and the second by the NMCA and
SME enzymes which, in contrast to all other SXXK
β-lactamases, hydrolyse carbapenems with high effi-
ciency. Despite these specificity differences, the tertiary
structures of all class A β-lactamases are nearly
superimposable.
The class C enzymes have Mr values of 39,000 and
exhibit more uniform properties. They hydrolyse
benzyl- and phenoxymethyl penicillin relatively well
(turn-over numbers of 20–70 s−1), ampicillin and
amoxicillin 10- to 20-fold less rapidly and extremely
poorly the other penicillins (generally due to low
k3 values). The early cephalosporins (cephalothin,
b-Lactam Antibiotics. Figure 3 Lipid II precursor (bottom) and polymeric (4–3) peptidoglycan of Escherichia coli
and Mycobacterium tuberculosis. Glycosyl transferase and acyl transferase-catalysed reactions. G: N-
acetylglucosamine. M: N-acetylmuramic acid. A2pm: meso-diaminopimelic acid. (3–3) Peptidoglycan cross linking
(Fig. 2) may proceed via the formation, in a penicillin-resistant manner, of a N-acyl-L-diaminoacyl moiety linked as an
ester to the serine residue and the transfer of the peptidyl moiety to theω-amino group of the diamino acid residue of
another peptide.
682 b-Lactam Antibioticscephalexin, cefazolin) are well hydrolysed but the later
generation compounds also exhibit low to very low
k3 values, as do imipenem and aztreonam. A few
mutations are known to extend the spectrum of some
enzymes but the most currently utilized bacterial
strategy is overproduction by deregulation of the
biosynthetic control mechanism, so that the MICs of
poor or even very poor substrates can increase
significantly [5].
Class D enzymes (Mr of about 27,000) exhibit a high
activity versus isoxazolyl penicillins, such as oxacillin
and are referred to as the OXA-family. Surprisingly,
the amino group of the SXXK lysine residues is
carboxylated in the most active forms of the enzymes.
Penicillins are generally better substrates than
cephalosporins but mutations have been found which
confer extended activity spectra to these enzymes.
Inactivators of class A β-lactamases (clavulanate,
sulbactam, tazobactam) are themselves β-lactams and
act as suicide substrates. They can be used incombination with β-lactamase sensitive compounds
(ampicillin, amoxicillin) but are not clinically useful
against class C and class D producers. Some TEM
mutants have also been selected that exhibit reduced
sensitivity to these inactivators.
The class B metallo-β-lactamases have emerged
more recently as a clinical problem but they are
particularly dangerous since many of them hydrolyse
all know β-lactams, with the exception of monobac-
tams. In particular, they hydrolyse the suicide substrates
mentioned above, as well as carbapenems that usually
escape the activity of all the SXXK enzymes, with the
exception of the NMCA group.
Three subclasses B1, B2 and B3 can be distin-
guished on the basis of the sequences. B1 and B3
enzymes are optimally active with 2 Zn2+ions, while the
B2 enzymes are inhibited by the second Zn2+. These B2
enzymes also exhibit a very narrow activity spectrum
and only hydrolyse carbapenems. The 3D structures of
representative members of each subfamily have been
b-Lactamases 683solved and they highlight a typical αββα fold,
completely unrelated to that of the SXXK enzymes.
The production of β-lactamases can be inducible or
constitutive and the genes carried by the chromosome
or plasmids, some genes being parts of integrons.
Several clinical strains produce up to three distinct
enzymes.LPBP-Mediated Resistance
There are at least two modes of intrinsic resistance to
β-lactam antibiotics. Determinants conferring a decreased
susceptibility to β-lactam antibiotics evolve by the
accumulation of point mutations in genes that code
for essential PBP fusions of classes A and/or B. The
shuffling and capture of DNA sequences from commen-
sal Streptococci having a reduced susceptibility to the
drug, give rise to S tre pt oc oc cu s p ne um on ia e pathogens in
which mosaic genes code for mosaic PBP fusions of
classes A and/or B of decreased affinity for the drug.
Mosaic and wildtype PBP fusions of the same class (and
the same subclass) differ by up to 15% amino acid
residues. Mosaic PBPs occur also in Neisseria meningi-
tidis and N e is se ri a g on or rh o e ae strains.
Other strategies leading to an increased resistance
are the transfer of a complete gene encoding a resistant
PBP from a non-pathogenic related species to yield the
Methicillin Resistant Staphylococcus aureus (MRSA)
and the overproduction by Enterococci of a pre-existing
but minor resistant PBP, which can further mutate to
even more resistant forms. Some bacteria can also
manufacture a (3 –3) peptidoglycan ( Fig. 2) with the
help of a penicillin-resistant LD -transpeptidase, which
is not an SXXK enzyme. Indeed, a low proportion of
(3–3) cross links have been found in the walls of
Enterococcus faecium , Mycobacterium tuberculosis
and Mycobacterium leprae . The quantitative influence
of these cross links on the resistance level remains to be
determined but the synthesis of (3–3) peptidoglycan,
combined with that of a set of relatively resistant SXXK
PBPs and the limited permeability of the mycolic acid
layer might explain the lack of efficiency of β-lactam
antibiotics as therapeutic agents against tuberculosis
and leprosy [6].
Outer Membrane Permeability and Active
Efflux Systems
In Gram-negative bacteria, diffusion of β-lactam
antibiotics into the periplasm (where the activity of
PBPs takes place) occurs via the channels that porins
create in the outer membrane. The number and
properties of the porin molecules are such that diffusion
is relatively rapid in E. coli but much slower in
Enterobacter and Pseudomonas. Mutants can be
selected after the permeability of porin channels or
their number has been decreased. A slow diffusion intothe periplasm becomes a particularly important factor
when it is combined with the presence of a β-lactamase
(even in low concentration or when poorly active) in the
same cellular compartment. Note that inMycobacteria,
the mycolic acid layer plays a role similar to that of the
outer membrane in Gram-negatives. Finally, β-lactams
bearing a hydrophobic side-chain can be ejected
from the periplasm by the active efflux systems
AcrAB-TolC in E. coli and Salmonella typhimurium
and MexAB-OprM in Pseudomonas. Overexpression
of these proteins can significantly increase the level
of resistance.Clinical Use
Because the SXXK PBPs are specific to the prokar-
yotes, the β-lactam antibiotics have a high selective
toxicity without marked side effects except for possible
allergic reactions. Resistance is a problem of great
concern. The use of antibiotics fuels the continuing
emergence and spreading of novel β-lactamases
and intrinsic resistance determinants among bacterial
pathogens.
▶Microbial Resistance to Drugs
▶Quinolones
▶Ribosomal Protein Synthesis Inhibitors
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684 Lateral Hypothalamic AreaLateral Hypothalamic AreaThe lateral hypothalamic area has been identified as a
feeding centre by studies involving electric stimulation
and discrete lesions. Neurons in the lateral hypothalam-
ic area and the neighbouring perifornical area express
neuropeptides that stimulate feeding when injected into
cerebral ventricles (orexins 1 and 2, melanin-concen-
trating hormone (MCH)).
▶Appetite Control
LaxativesLaxatives, also called purgatives or cathartics, are
substances used to hasten the transit of food through the
intestine. Laxatives function by different mechanisms.
Bulk laxatives, like methylcellulose or bran, contain
agents like polysaccharide polymers, which are not
fermented by the normal processes of digestion. They
retain water in the gut lumen and promote bowel
movements. Osmotic laxatives consist of poorly
absorbable solutes such as salines containing magne-
sium cations or phosphate anions or non-digestable
sugars and alcohols (glycerin, lactulose, sorbitol or
mannitol). Osmotic laxatives retain an increased
volume of fluid in the lumen of the bowel by osmosis,
which accelerates the transfer of the bowel contents.
Faecal softeners alter the consistency of the faeces.
They are also called emollients and contain surface-
active compounds similar to detergents, like docusate
salts. Stimulant laxatives/purgatives increase the motil-
ity of the gut (peristalsis) and stimulate water and
electrolyte secretion by the mucosa. Stimulant laxa-
tives, which can cause abdominal cramps and deterio-
ration of intestinal function, include diphenylmethane
derivatives (bisacodyl, phenolphthalein), anthraqui-
none laxatives (derivatives of plants such as aloe,
cascara or senna) and ricinoleic acid.
LCAT▶Lecithin-Cholesterol AcyltransferaseLD50▶Lethal Dose
LDL-Cholesterol▶Low-Density-Lipoprotein
LDL-ReceptorsLDL-receptors are receptors on the cell surface that
remove LDL (and some other forms of) lipoproteins
from the plasma into the cell.
▶HMG-CoA-Reductase Inhibitors (Statins)
▶Lipoprotein Metabolism
▶Low-Density Lipo-protein Receptor Gene Family
LeadA lead is a hit compound that displays specificity and
potency against a target in a library screen and continues
to show the initial positive dose-dependent response in
more complex models such as cells and animals.
Lead Discovery by NMR▶SAR-by-NMR




LeptinLThe cytokine leptin is secreted by adipocytes (fat cells) in
proportion to the size of the adipose depot and circulates
via the bloodstream to the brain, where it ultimately
affects feeding behavior, endocrine systems including
reproductive function and, at least in rodents, energy
expenditure. The major effect of Leptin is on the hy-
pothalamous,where it suppresses appetite andhence food
intake. Leptin exerts its effects via binding to the leptin
receptor in the brain (specifically in the hypothalamus),
which activates the JAK-STAT Pathway.
▶Appetite Control
▶Adipokines
Lethal DoseThe lethal dose (LD50) is a measure of the toxicity of a
compound. In an LD50 toxicity test, various doses of a
drug are administered to groups of animals, and the
mortality in each group is determined. The lethal dose 50
is the dose,which is lethal for 50%of a group of animals.
Leucin ZipperA leucine zipper is a structural motif present in a large
class of transcription factors. These dimeric proteins
contain two extended alpha helices that “grip” the DNA
molecule much like a pair of scissors at adjacent major
grooves. The coiled-coil dimerization domain contains
precisely spaced leucine residues which are required for
the interaction of the two monomers. Some DNA-
binding proteins with this general motif contain other
hydrophobic amino acids in these positions; hence, this
structural motif is generally called a basic zipper.LeukotrienesALAN R. LEFF, NILDA M. MUN˜OZ





Leukotrienes belong to a large family of lipid
mediators, termed eicosanoids, which are derived from
arachidonic acid (AA) and released from the cell
membrane by phospholipases. AA is subsequently
converted by the enzyme, 5-lipoxygenase (5-LO) and a
protein cofactor, ▶5-lipoxygense activating protein
(FLAP), into two bioactive classes of leukotriene
(LT): (i) LTB4 and (ii) ▶cysteinyl leukotrienes
(cysLTs), LTC4, D4, and E4. Leukotrienes do not exist
in the state preformed in cells. These compounds play a
significant role in allergic responses and contribute
variably to the bronchoconstrictor response in human




The site of synthesis of leukotrienes is largely or
completely in the nuclear membrane. LTs are produced
fromcellmembranephospholipid-associated arachidonic
acid (AA), which is liberated by 85 kDa cytosolic group
IVAPLA2 (cPLA2) (Fig. 1) or phospholipase C (not
shown) in response to cell activation. The secretory
phospholipase group V PLA2 (gVPLA2) also is capable
of inducing leukotriene synthesis, probably from phos-
phatidylcholine-rich membrane hydrolysis at both plas-
ma or perinuclear membrane [1]. AA is converted to 5-
HETE and subsequently to an unstable epoxide LTA4
([5(s)-trans-5,6-oxido-7,9-trans11,14-cis-eicosatetra-
nonic acid]), a central intermediary in LT biosynthesis.
LTs are synthesized in the cells by 5-LO which acts in
concert with FLAP, a protein essential for 5-LO to
function enzymatically in intact cells. In neutrophils,
LTA4 is transformed by LTA hydrolase to dihydroxy
LTB4,whereas in▶eosinophils,macrophages, basophils,
and mast cells that express LTC4 synthase, the terminal
enzyme involved in cysLT synthesis, LTA4 is conjugated
with the tripeptide glutathione to form LTC4. Outside of
the cell, LTC4 is rapidly converted by γ-glutamyltran-
speptidase into LTD4. LTD4 is converted more slowly
into LTE4 by a dipeptidase, which is secreted into the
urine and is sometimes used (controversially) as amarker
for cysLT synthesis. Leukotriene B4, a noncysteine
Leukotrienes. Figure 1 Schema representing cellular biosynthesis of cysteinyl leukotrienes (cysLTs) and BLTat the
nuclear membrane. In this schema, cPLA2 has migrated from the cytosol to the nuclear envelope and 5-LO is
secreted from the nucleus to bind with FLAP and produce the metabolite, LTA4, which is synthesized by 5-LO from
5-HPETE (not shown) in two steps. LTA4 is converted by LTC4 synthase which after LTC4, is converted rapidly to
LTD4 outside of the inflammatory cell. Note that a specific hydrolase (LTA4 hydrolase) also catalyzes the formation of
LTB4, a non-cysLT, which has its own receptor. See text for details.
686 Leukotrienescontaining dihydroxy leukotriene, binds to its own BLT
receptor. The cysLTs are characterized by a side chain
containing 3, 2, or 1 amino acid(s) (cysteine is always
present); there are twoormore specific cysLTreceptors in
tissues at various sites including airway smooth muscle,
vascular smooth muscle, and inflammatory cells them-
selves. Both cysLT receptors have been characterized and
cloned. LTD4 binds to high affinity CysLT1 receptor
while CysLT2 receptor is most preferred target for LTC4.
Recent investigations have suggested that cysLTmay
also be synthesized in the cytosol in lipid bodies that are
formed during cellular activation in eosinophils [2].
It has been suggested that all enzyme and transport
systems essential to cysLT synthesis exist in these
lipid bodies, and hence synthesis could occur without
translocation of cPLA2 to the nuclear envelope.
Likewise, it has been suggested that 5-LO is not stored
within the nucleus, but rather is an enzyme dispersed
throughout the cytosol, which migrates to the peri-
nuclear membrane and cytosolic lipid bodies upon
cellular activation. Recently, the role of 14 kDa
secretory PLA2 in leukotriene synthesis has been
explored in human granulocytes [1]. Studies demon-
strated that gVPLA2 is capable of causing AA synthesis
and subsequent LT secretion by both cPLA2-dependent
and -independent pathways. Among the secretory
enzymes, gVPLA2 is unique because it can bind cell
membranes by two distinct mechanisms: (i) cell surface
proteoglycan through a cluster of cationic residues at
the carboxy terminus of the enzyme and (ii) direct
interfacial binding to membrane phosphatidylcholine.
In eosinophils, gVPLA2 is internalized and binds to
perinuclear membrane to generate AA and subsequenttranslocation of cytosolic 5-LO to perinuclear mem-
brane. Accordingly, LTC4 secretion caused by gVPLA2
in eosinophils does not involve ERK-1/2 mediated
cPLA2 phosphorylation. By contrast, LTB4 secretion
caused by gVPLA2 in neutrophils is mediated through
activation of the cPLA2 pathway. These novel pathways
for gVPLA2 are fully established in granulocytes;
however, the role of other 14 kDa sPLA2 isoforms in LT
synthesis in vitro remains an area of considerable
interest. sPLA2s have been identified in the bronch-
oalveolar lavage fluid of asthmatic subjects.
Leukotriene Receptors
There are two distinct receptor types for LTB4 (BLT1
and BLT2 receptors) and two for cysLTs (CysLT1 and
CysLT2 receptors). Classification is based mainly on
functional data as derived from recent cloning and
biochemical characterization. For LTB4, high affinity
BLT1-receptor shows high degree of specificity for
LTB4 (Kd 0.15–1 nM) and is only expressed in
inflammatory cells. Recently identified low affinity
BLT2-receptor has a higher Kd value for LTB4 (23 nM)
and is expressed ubiquitously, in contrast to BLT1,
in leukocytes.
The cysLTs are a family of potent bioactive lipids that
act through two structurally divergent G protein
coupled CysLT1 and CysLT2 receptors. mRNA expres-
sion demonstrates the CysLT1 gene, which is located on
the X chromosome and is identified in macrophages,
smooth muscle cells, leukocytes, lung, and spleen. The
CysLT1 receptor was originally identified on the basis
of its contractile properties for bronchial smooth
muscle. The agonist for the CysLT1 receptor are
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LLT D4 > LTC4 > LTE4. The second receptor, CysLT2,
binds equally to LTD4 and LTC 4; mRNA is expressed in
heart, leukocytes, spleen, brain, placenta, and lymph
nodes. To date, the functional role of CysLT2 receptor
remains unclear. The current nomenclature is summar-
ized in Table 2, together with order of potency of the
LTs, names of some selective antagonist drugs and
expression in human and mouse tissues/cells.
Role of Leukotrienes in Inflammatory Diseases
LT B4, a B- leukotr ie ne, is a p ot ent c hemotax in for
neutr ophils and T-cells and a wea k ch em otaxin for human
eosin ophils. In human ne ut roph ils , LTB4 caus es t ranslo -
cation o f i ntrace llu lar calc iu m th at in itiates an au tocrine
patter n of stimulated cellula r ac tivity. It promo tes the
adhe si on of n eutrop hils to the v ascu lar en dothe li um and
enha nces th e m igration a cross t h e endo thelial w all i nto t he
surro unding tissues . LTB4 also causes the release of toxic
oxyg en r adica ls , l yso somal e nzymes , an d ch emokine s/
cytok ines from pro in fl ammatory ce ll s. Some stud ies have
shown tha t LTB4 ma y cause contra ction of b ot h human
bron chus and guin ea pig p arenc hymal strips in vitro ;
however, blockade of LTB4 rece pt or has little o r no
thera peutic a ction i n h um an asth ma .
The cysLTs were formerly known as SRS-A (slow
reacting substance of anaphylaxis) because of the slow,
sustained contraction of airway smooth muscle that
resulted from the secretion of this substance(s) upon mast
cell activation. Human bronchi may have a homogenous
population of CysLT1 receptors, whereas guinea pig
trachea have both CysLT1/2 receptors. Although original-
ly identified in tissue mast cells, eosinophils, and mast
cells, both have substantial cysLT synthetic capacity.
Because the eosinophil is ubiquitous in asthma and
allergic disease and because it is capable of cysLT
synthesis, this cell has generally been regarded as primary
mechanism for sustained cysLT secretion in allergic states
(Ta b l e 1 ). However, recent publications have suggested
the eosinophil secretion is relatively minimal compared to







Stimulation of PLA2 (guinea pig)
Contraction of human bronchus (?)
Contraction of guinea pig parenchyma (?)
No effect with LTRA
Reprinted with permission from [3].Asthmatic exacerbations are associated with chemo-
taxis of eosinophils from the peripheral blood across
endothelial membranes into the parenchyma and lumen
of the conducting airways of the lung. This process is
facilitated by the upregulation of β1- and β2-integrins,
which bind to counterligands of the immunoglobulin
supergene family on the endothelial surface. Diapedesis
is facilitated by the presence of these ligands on both
sides of the endothelium (lumenal and parencymal).
The migration of eosinophils from the peripheral blood
to human airways provides a continuous reservoir for
leukotriene synthesis in allergic and asthma reactions.
The 85 kDa cPLA2 that catalyzes the first steps of
leukotriene synthesis also serves as a messenger protein
for cellular adhesion, likely by the synthesis of
lysophospholipid, which is the by-product of mem-
brane hydrolysis in which AA is also synthesized.
Leukotrienes play a role in both allergy and asthma
[5]. While cysLTs are highly efficacious bronchocon-
stricting agents when administered exogenously to
human asthmatics (Fig. 2) (1000-fold the potency of
histamine), a substantial role for cysLT in asthmatic
bronchoconstriction has not been established. Amelio-
ration of inflammatory response by corticosteroids in
both asthma and allergic reactions is highly efficacious
and does not appear to result from blockade of
leukotriene synthesis. No other chronic inflammatory
disease has been linked directly to cysLT secretion
despite the capacity for these compounds to cause
edema and inflammatory cell migration.
Drugs
The effects of leukotrienes can be blocked at several
levels. Inhibitors of FLAP or 5-LO inhibit LTsynthesis at
all levels. However, FLAP antagonists developed to date
have been too hepatotoxic for human use. Zileuton, a
5-LO synthase inhibiting drug, also demonstrated some
hepatotoxicity in a small percentage of patients, which
was nonetheless entirely reversible. However, the short
half-life of this compound requires four times dailyienes
Cysteinyl LTs (LTC4, LTD4, LTE4)
Airway smooth muscle contraction
Constriction of conducting airways
Contraction of guinea pig parenchyma
Secretion of mucus
Fluid leakage from venules
Edema formation
Chemoattraction of eosinophils
Autocrine activation of PLA2 (guinea pig)
Blocked by LTRA
688 Leukotrienesadministration, and accordingly, this compound is rarely
prescribed. The most widely used antiLT drugs are the
▶leukotriene receptor antagonists (LTRAs; see Table 2),
which were synthesized before the cloning of the CysLT1
receptor. These include pranlukast, which is widelyLeukotrienes. Table 2 Leukotriene receptor type [4]
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aPartial agonist in some tissues.
Leukotrienes. Figure 2 Relative airway responses of
asthmatic patients to inhaled cysteinyl leukotrines
versus histamine. CysLTs have up to 1,000-fold greater
potency in causing bronchoconstriction than histamine.
Reprinted with permission from (2).used in Japan, and zafirlukast andmontelukast, which are
used in the USA, Europe, and Asia. In controlled studies
in human asthmatics, these compounds cause 5–8%
improvement in bronchoconstriction as measured by the
forced expiratory volume in 1 s (FEV1). LTRAs have
been shown to reduce the need for inhaled corticosteroids
(ICS) and β-adrenoceptor agonists in human asthma.
Additional studies have suggested that addition of
LTRA to ICS or β- adrenoceptor agonists augments the
improvement in FEV1. Nonetheless, LTRAs are fairly
expensive and substantially less efficacious than
either long-acting β-adrenergic agonists (LABA) or
ICS, particularly when LABA and ICS are used in
combination. Accordingly, the use of LTRAs is often
relegated to either mild asthma or as supplemental
therapy for patients failing to respond to other drugs.
There are few definitive data to substantiate the
efficacy of LTRA therapy in refractory asthma, except
for patients with “aspirin-sensitive asthma.” This is a
fairly uncommon form of asthma that occurs generally
in adults who often have no prior (i.e., childhood)
history of asthma or▶atopy, may have nasal polyposis,
and who often are dependent upon oral corticosteroids
for control of their asthma. This syndrome is not
specific to aspirin but is provoked by any inhibitors of
the cycloxygenase-1 (COX-1) pathway. These patients
have been shown to have a genetic defect that causeseptor (LTD4 receptor) CysLT2 receptor (LTC4 receptor)
4 > LTE4
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phils, cardiac muscle, coronary
artery, PBLs
g, skin, small intestine
phages, fibroblasts,
Tissues: lung, skin, brain, small




Loverexpression of the enzyme LTC4 synthase. Howev-
er, the mechanism by which bronchoconstriction is
provoked by COX-1 inhibition remains unexplained. In
such patients, LTRAs are specifically indicated. There
is limited evidence suggesting that patients with aspirin-
sensitive asthma can use selective COX-2 inhibitors
safely; however, COX-2-specific analgesics still are not
recommended for use in aspirin-sensitive asthma by the
FDA in the USA and may themselves be cardiotoxic.
Although some studies have shown no change in the
excretion of LTE4 in the urine of patients treated with
corticosteroids, other investigations indicated that corti-
costeroids inhibit cPLA2 translocation to the nuclear
membrane in inflammatory cells, thus attenuating
stimulated synthesis of cysLTs. This would suggest
that oral and possibly inhaled corticosteroids may also
inhibit production of cysLTs both directly (see above)
and indirectly by causing necrosis and apoptosis of
eosinophils.
In the USA, LTRAs have largely replaced theophyl-
line as the incremental drug for the treatment of
moderate and severe asthma, where LABA plus ICS
alone do not provide adequate control. For patients with
mild persistent asthma, LTRAs have been designated as
a suitable substitute for low dose ICS by the National
Asthma Education Panel Program (NAEPP) of the
National Heart and Lung Institute (National Institutes of
Health). However, inhaled ICS are more efficacious.
Therapeutic Response to Antileukotriene Drugs
When given acutely to patients who have no prior
exposure to LTRA therapy, FEV1 increases measurably
within 30 min and results in a maximal improvement of
about 8% in 1 h. For short acting drugs (e.g., zileuton),
this response returns rapidly to baseline, and the drug
must initially be administered in four doses daily. In this
regard, the initial effects of 5-LO inhibition are more
like bronchodilators than disease modifying agents.
However, with prolonged use (>60 days), there is little
difference between peak and trough response in FEV1,
even if zileuton administration is decreased to twice
daily. This acquired, longer acting effect has been
suggested to imply a disease modifying effect of
antileukotriene therapy. In some studies, even acute
administration of LTRAs has caused a modest decrease
in eosinophil migration into asthmatic airways and
the presence of the cysLT receptor, which has been
recently identified on eosinophils, suggests a possible
mechanism for this action. Other recent studies indicate
that the LTRA, montelukast, if infused intravenously
causes rapid incremental increase in FEV1 in patients
seeking treatment for acute asthma. The reason for
the improved efficacy by intravenous infusion is
unclear, but further investigations are examining the
future role of LTRAs as potential rescue drugs in acute
asthma.LTRAs are extremely safe for patient use. However,
the present generation of LTRAs is only modestly
efficacious. Many patients show no clinically meaning-
ful response, and current recommendations suggest a 1
month trial period to determine if patients will benefit
from these drugs. With the exception of aspirin-
sensitive asthmatics, there is currently no means for
predicting which patients or under what circumstances
antileukotrine therapies will be effective.
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Lewy BodiesLewy bodies are typical in neuronal degeneration,
which is accompanied by the presence of these
eosinophilic intracellular inclusions of 5–25 μm
diameter in a proportion of still surviving neurons.
Lewy bodies contain neurofilament, tubulin, microtu-
bule-associated proteins 1 and 2, and gelsolin, an actin-
modulating protein.
▶Anti-Parkinson Drugs
690 LH-RH AgonistLH-RH AgonistLH-RH (Luteinizing Hormone-Releasing Hormone)
agonists are drugs that inhibit the secretion of sex
hormones. In men, LH-RH agonists cause testosterone
levels to fall. In women, LH-RH agonists cause the
levels of estrogen and other sex hormones to fall.
▶Contraceptives
▶Targeted Cancer Therapy
Liddle’s SyndromeLiddle's syndrome is an autosomal dominant disorder
that is caused by persistent hyperactivity of the
epithelial Na channel. Its symptoms mimic aldosterone
excess, but plasma aldosterone levels are actually
reduced (pseudoaldosteronism). The disease is char-
acterized by early onset arterial hypertension, hypoka-
lemia, and metabolic alkalosis.
Disease-causing mutations are found in the cytoplas-
mic regulatory region of the β and γ subunits of the
epithelial sodium channel (ENaC) genes. In general,
patients with Liddle's syndrome can be treated
successfully with the ENaC inhibitor amiloride.
▶Diuretics
▶Epithelial Na+ Channels
LigandA ligand can be an antagonist or agonist that binds to a
receptor.
Ligand-Gated Ion ChannelsIon channels that are opened by binding of a
neurotransmitter (or drug) to a receptor domain on
extracellular sites of the channel protein(s) are definedas ligand-gated. Nicotinic acetylcholine, glutamate,
γ-aminobutyric acidA (GABAA) and glycine receptors













Limbic SystemCollection of interconnected subcortical and cortical
brain structures (including hypothalamus, amygdala,
and hippocampus) integrating multimodal intero- and
exteroceptive information to produce coherent neuro-
endocrine and behavioral output, and to support
memory functions.
▶OrexinsLinkage Disequilibrium (LD)Polymorphisms in the human genome are often not
independently transmitted; i.e., a polymorphism is
associated with particular variants present on the same
chromosome. Recombination erodes this association,
but for physically close polymorphisms (e.g., within a
gene), the correlation, known as LD, persists over time.
▶Pharmacogenomics
Lipid-lowering DrugsLipid-lowering drugs are drugs that affect the lipopro-
teinmetabolism and that used in therapy to lower plasma
lipids (cholesterol, triglycerides). The main classes of
Lipid Modifications 691drugs used clinically are statins (HMG-CoA reductase
inhibitors), anion exchange resins (e.g. cholestyramine
and cholestipol), fibrates (bezafibrate, gemfibrozil or
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Synonyms
Lipidation; S-acylation; N-myristoylation; Myristoy-
lation; S-prenylation; Prenylation; Palmitoylation;
Isoprenylation; ▶GPI anchors; GlypiationLipid Modifications. Figure 1 Major classes of lipid-modiDefinition
Covalent attachment of lipid moieties to proteins plays
important roles in the cellular localization and function
of a broad spectrum of proteins in all eukaryotic cells.
Such proteins, commonly referred to as lipidated
proteins, are classified based on the identity of the
attached lipid (Fig. 1). Each specific type of lipid
has unique properties that confer distinct functional
attributes to its protein host. S-acylated proteins,
commonly referred to as palmitoylated proteins,
generally contain the 16-carbon saturated acyl group
palmitoyl attached via a labile thioester bond to cysteine
residue(s), although other fatty acyl chains may
substitute for palmitoyl group.N-myristoylated proteins
contain the saturated 14-carbon myristoyl group
attached via amide bond formation to amino-terminal
glycine residues. S-prenylated proteins contain one of
two▶isoprenoid lipids, either the 15-carbon farnesyl or
20-carbon geranylgeranyl. The fourth major class of
lipidated proteins is those containing the glycosylpho-
sphatidylinositol (GPI) moiety, a large and complex
structure of which the lipid component is an entire
phospholipid.Basic Mechanisms
S-acylated proteins include many GTP-binding regu-
latory proteins (G proteins), including most α subunits
of ▶heterotrimeric G-proteins and also many members
of the Ras superfamily of monomeric G proteins, a
number of G protein-coupled receptors, several non-
receptor ▶tyrosine kinases, and a number of other
signaling molecules. S-acylation is posttranslational
and reversible, a property that allows the cell to controlfied proteins.
692 Lipid Modificationsthe modification state, and hence the localization and
biological activity, of the protein [1]. The lipid
substrates for S-acylation are ▶acyl-CoA mole-
cules. The molecular mechanism of S-acylation is
only recently being elucidated; the first identified
acyltransferase specifically involved in the process
being the product of the Skinny Hedgehog (Ski)
gene in Drosophila. Ski orthologs have also been
identified in mammalian genomes. This acyltransferase
appears to specifically process secreted proteins, in
particular a molecule important in development termed
Hedgehog.
The process by which cytoplasmic proteins are
subject to S-acylation is also becoming clarified. The
breakthrough in this arena came from genetic screens in
yeast, in which two related S-palmitoyltransferases were
uncovered that are termed Erf2 and Akr1. These two
gene products share a common sequence referred to as a
DHHC (aspartate-histidine-histidine-cysteine) motif,
and a large number of genes encoding DHHC-motif
proteins can be identified in all eukaryotes for which
genome information is available. Although biochemical
details of the enzymatic function of DHHC-motif
proteins are still rather limited, the available evidence
is consistent with the DHHC domain playing a direct
role in the protein acyltransferase reaction.
In addition, nonenzymatic acylation of cysteine
thiols on proteins incubated in the presence of acyl-
CoA has been described, although the biological
importance of this process is still unclear.
N-myristoylated proteins include select α subunits of
heterotrimeric G proteins, a number of nonreceptor
tyrosine kinases, a few monomeric G-proteins, and
several other proteins important in biological regulation
[2]. There is some overlap between S-acylated and
N-myristoylated proteins such that many contain both
lipid modifications. Such “dual lipidation” can have
important consequences, most notably the localization
of the dually modified species to distinct membrane
subdomains termed ▶lipid rafts or ▶caveolae.
N-myristoylation is a stable modification of proteins.
The myristoyl moiety is attached to the protein
cotranslationally by the enzyme myristoyl CoA: protein
N-myristoyltransferase (NMT); the lipid substrate is
myristoyl-CoA. NMT has been extensively studied in
regard to substrate utilization and kinetic properties,
and crystal structures of fungal enzymes are available.
There are two distinct but closely related genes
encoding NMTs in mammalian cells, NMT1 and
NMT2, although differences between the two isoforms
have not yet been described.
S-prenylation is the most recent of the four major
types of lipid modifications to be described. As with
S-acylation, S-prenylation is posttranslational. The lipid
substrates for these modifications are farnesyl diphos-
phate and geranylgeranyl diphosphate. The mechanisminvolves attachment of the isoprenoid lipid to cysteine
residues at or near the carboxyl terminus through a
stable thioether bond [3]. Two distinct classes of
S-prenylated proteins exist in eukaryotic organisms.
Proteins containing a cysteine residue fourth from
the carboxyl terminus (the so-called CaaX-motif) can
be modified by either the 15-carbon farnesyl or 20-
carbon geranylgeranyl isoprenoid by one of two closely
related termed protein farnesyltransferase (FTase) and
protein geranylgeranyltransferase type 1 (GGTase-1);
these enzymes are collectively referred to as CaaX
prenyltransferases [4]. FTase and GGTase-1 are αβ
heterodimers; the α subunits of the enzymes are
identical while the β subunits are the products of
distinct, but related, genes. The identity of the “X”
residue of the CaaX motif dictates which of the two
enzymes recognize the substrate protein. Following
prenylation, most CaaX-type proteins are further
processed by proteolytic removal of the three carbox-
yl-terminal residues (i.e., the -aaX) by the Rce1 CaaX
protease and methylation of the now-exposed carboxyl
group of the prenylcysteine by the Icmt methyltransfer-
ase. A number of S-prenylated proteins are also subject
to S-acylation at a nearby cysteine residue to produce a
dually lipidated molecule, although this type of dual
modification does not apparently target the protein to
the same type of membrane subdomain as the dual
acylation noted above.
The second class of S-prenylated proteins is a
member of the Rab family of proteins, which is
involved in membrane trafficking in cells. These
proteins are geranylgeranylated at two cysteine residues
at or very near to their carboxyl-terminus by protein
geranylgeranyltransferase type 2 (GGTase-2), also
known as Rab GGTase [5]. GGTase-2 is also a αβ
heterodimer and its subunits show significant se-
quence similarity to the corresponding subunits of the
CaaX prenyltransferases [6]. However, unlike the CaaX
prenyltransferases, monomeric Rab proteins are not
substrates for GGTase-2. In order to be processed by the
enzyme, newly synthesized Rab proteins first bind and
form a stable complex with a protein termed Rep, and it
is the Rab–Rep complex that is recognized by GGTase-
II. The enzyme acts in a processive fashion, attaching
both geranylgeranyl groups to closely spaced cysteine
residues at or near the carboxyl-terminus of the Rab
proteins. All three of the protein prenyltransferases
(FTase, GGTase-1, GGTase-2) have been extensively
characterized in regard to substrate recognition, mecha-
nism, and structure.
GPI-anchored proteins constitute a quite diverse
family of cell-surface molecules that participate in
such processes as nutrient uptake, cell adhesion, and
membrane signaling events [3]. All GPI-linked pro-
teins are destined for the cell surface via trafficking
through the secretory pathway, where they acquire the
Lipid Phosphate Phosphohydrolases 693
Lpreassembled GPI moiety. The entire procedure, which
involves assembly of the GPI moiety from ▶phospha-
tidylinositol and sugars and proteolytic processing of
the target protein to expose the GPI addition site at the
carboxyl-terminus of the protein, involves a number of
gene products. Many of the genes associated with GPI
biosynthesis have been cloned by complementation of
GPI-deficient mammalian cell lines and temperature-
sensitive yeast GPI mutants. The precise mechanisms
through which these enzymes work in concert to
produce a GPI-anchored protein are just now beginning
to be elucidated.
Pharmacological Intervention
Since the mechanisms of protein S-acylation are so
poorly understood, there is little in the way of good
pharmacological agents that target this process. One
compound that has been used with modest success is
cerulenin, which apparently mimics the acyl-CoA
substrate in the reaction catalyzed by the putative
S-acyltransferase that acts on intracellular proteins. In
contrast, there has been substantial effort to identify and
characterize specific inhibitors of N-myristoylation [2].
Genetic and biochemical studies have established NMT
as a target for development of anti-fungal drugs. The
enzyme is also a potential target for the development of
antiviral and antineoplastic agents. Both peptidic and
nonpeptidic inhibitors of NMTs, particularly fungal
NMTs, have been described.
There has been enormous effort in the past 10 years to
develop pharmacological agents targeting the S-pre-
nylation by CaaX prenyltransferases, especially FTase
[4]. This is primarily due to the interest in one subset
of S-prenylated proteins, the Ras proteins, due to the
important role of Ras in▶oncogenesis. Ras proteins are
modified by the 15-carbon farnesyl isoprenoid, and
farnesylation of these proteins is indispensable for both
normal biological activity and oncogenic transforma-
tion. Selective inhibitors of FTase, termed FTIs, can
reverse Ras-mediated oncogenic transformation of
cells, and several are in clinical development as
anticancer therapeutics. Literally hundreds of potent
inhibitors of FTase, and many of GGTase-1, have been
identified using several strategies, including design of
analogs of the CaaX peptide and isoprenoid substrates
and by high-throughput screening of natural product
and compound libraries. These compounds can be
placed into four distinct categories: mimics of CaaX
tetrapeptides, mimics of FPP,▶bisubstrate analogs, and
organic compounds selected from natural product
and chemical libraries. There has been relatively little
development of pharmacological agents targeting
GGTase-2. It is likely, however, that some of the
isoprenoid analogs that show activity against GGTase-1
will also have inhibitory activity on GGTase-2 given
that both enzymes use the same isoprenoid substrate.There is also increasing interest in developing
pharmacological agents targeting the biosynthesis of
GPI-anchored proteins [3]. Such proteins are particu-
larly abundant on the surface of a number of protozoan
organisms. Several devastating tropical diseases such
as African sleeping sickness and Chagas disease are
caused by protozoan parasites that rely heavily on
cell-surface GPI-anchored proteins for both inhabiting
their host and escaping immune detection. In studies
primarily involving gene disruption approaches, sev-
eral of the enzymes involved in GPI biosynthesis
have been identified as attractive targets for develop-
ment of antiparasitics. To date, there is very little
publically available information on specific inhibitors
of the enzymes involved in GPI biosynthesis and
attachment, but it is likely that such information will be
forthcoming.
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Lipid Phosphate PhosphohydrolasesLipid phosphate phosphohydrolases (LPPs), formerly
called type 2 phosphatidate phosphohydrolases (PAP-2),
catalyse the dephosphorylation of bioactive phospholi-
pids (phosphatidic acid, ceramide-1-phosphate) and
lysophospholipids (lysophosphatidic acid, sphingosine-
1-phosphate). The substrate selectivity of individual
LPPs is broad in contrast to the related sphingosine-1-
phosphate phosphatase. LPPs are characterized by a
lack of requirement for Mg2+ and insensitivity to
N-ethylmaleimide. Three subtypes (LPP-1, LPP-2,
LPP-3) have been identified inmammals. These enzymes
have six putative transmembrane domains and three
highly conserved domains that are characteristic of a
phosphatase superfamily. Whether LPPs cleave extracel-
lularmediators or rather have an influence on intracellular
lipid phosphate concentrations is still a matter of debate.
694 Lipid RaftsLipid RaftsLipid rafts are specific subdomains of the plasma
membrane that are enriched in cholesterol and sphin-
golipids; many signaling molecules are apparently
concentrated in these subdomains.
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Synonyms
Plasma lipid transfer proteins
Definition
Plasma lipid transfer proteins, which include the
cholesteryl-ester-transfer-protein (CETP; previously
known as lipid transfer protein I, LTP-I) and the
phospholipid-transfer-protein (PLTP; previously
known as lipid transfer protein II, LTP-II) mediate the
transfer of lipids (cholesteryl esters, triglycerides and
phospholipids) between lipoproteins present in human
plasma. These proteins significantly affect plasma
lipoprotein concentration and composition.
Basic Characteristics
Gene and Protein Characteristics
The genes coding for CETP and PLTP belong to one
gene family, which also includes lipopolysaccharide-
binding-protein (LBP) and bactericidal/permeability-
increasing-protein (BPI). This common descent not only
becomes clear from a considerable sequence similarity
(45–65% homology at the cDNA level), but also from
substantial conservation of exon/intron transitions.
The gene encoding CETP is located on the long arm
of chromosome 16 (16q12-21), spans approximately
25kbp and harbors 16 exons and 15 introns. The
molecule mass of its mature protein product is 74 kDa.
Major sites of CETP gene expression in humans are theliver, spleen and adipose tissue, with lower levels of
expression in the small intestine, adrenals, kidney and
heart. CETP present in human plasma seems to originate
predominantly from the liver and adipose tissue,
although data that have assessed this directly in man are
lacking. The majority of human plasma CETP (90%)
is bound to ▶high-density lipoprotein (HDL) particles.
An important regulatory factor of CETP gene expres-
sion is hypercholesterolemia, which induces gene
transcription. Sequences necessary for this cholesterol-
responsiveness are located in the natural flanking
regions of the human CETP gene, upstream of the
transcription start site. This regulatory sequence con-
cerns an element of two direct repeats separated by four
nucleotides (DR4 element). This element enhances
CETP gene expression following activation through a
heterodimer, containing the transcription factors LiverX
Receptor (LXR) and Retinoid X Receptor (RXR). In
order to enhance gene transcription, these transcription
factors require activation through ligands,which include
cholesterol and its oxysterols.
The gene coding for PLTP has been mapped to
chromosome 20 (20q12-13.1), where also the genes for
LBP and BPI are situated. The PLTP gene contains 13.3
kbp, with similar organization as compared to CETP
(16 exons-15 introns). Purified PLTP has a molecule
mass of 81 kDa. PLTP is expressed in a variety of tissues
including placenta, pancreas, lung, kidney, heart, liver,
adipose tissue, skeletal muscle and brain. Macrophages
also express PLTP and may contribute significantly
to plasma PLTP activity levels. PLTP gene expression
can be upregulated by cholesterol in a similar way as
described for CETP. In addition, PLTP gene expression
is subject to regulation via response elements for
the peroxisome proliferator activated receptor (PPAR)
alpha and the farnesoid X-activated receptor (FXR).
Detailed protein structures have been reported for
BPI and CETP. Given the aforementioned similarities
within this gene family, these protein structures serve as
a likely model for the protein structure of PLTP. CETP
and BPI are elongated molecules, shaped like a
boomerang. There are two domains with similar folds,
and a central beta-sheet domain between these two
domains. The molecules contain two lipid-binding
sites, one in each domain near the interface of the
barrels and the central beta-sheet.
Function
In humans, CETP and PLTP are directly involved in
the transfer of lipids between different ▶lipoprotein
classes. Through their action, these lipid transfer
proteins have major effects on the concentration and
composition of HDL. This section further describes the
physiological function of CETP and PLTP in humans.
CETP mediates the exchange of cholesteryl esters and
triglycerides between HDL and the proatherogenic,
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LapoB-containing lipoprotein fractions, predominantly
▶very-low density lipoprotein (VLDL). Specifically,
triglycerides are transported from VLDL to HDL, with
cholesteryl esters transferred in the opposite direction. It
is generally acknowledged that CETP itself has no
preference for the type of lipoprotein in its substrate
specificity. The VLDL–HDL axis is likely to result from
the presence of plasma lipid transfer inhibitor protein
(LTIP), which is associated almost exclusively with
▶low-density lipoprotein (LDL) and inhibits the CETP-
mediated transfer of cholesteryl esters and triglycerides.
LTIP suppresses the involvement of LDL, thereby direct-
ing the CETP activity towards the remaining lipoprotein
fractions, VLDL and HDL. The CETP-mediated lipid
exchange is an equimolar and energyneutral process. The
exchange seems to occur by a shuttle mechanism, rather
then by the formation of a complex between CETP and
donor and acceptor lipoproteins. In addition to LTIP,
composition and concentration of lipoprotein substrates
are important regulatory factors of the CETP-mediated
exchange activity, and under physiological conditions,
the net mass of VLDL-triglycerides may be rate limiting.
The relevance of CETP for human lipid metabolism
became evident after the identification of humans with
partial or near complete loss of CETP activity due to the
presence of a mutation in one or both alleles of the CETP
gene. In these subjects, who predominantly live in Japan,
(partial) loss of plasma CETP reduces the ability of
cholesteryl esters to be transported out of HDL. This
results in a net increase in plasmaHDLcholesterol (HDL-
C) levels, with the appearance of HDL particles that have
increased in size. This change is paralleled by increased
concentrations of ▶apolipoprotein A-I (apoA-I), which
results from delayed catabolism of these large sized
HDLs. In some cases of severe CETP deficiency, the
reduced transfer of cholesteryl esters fromHDL toVLDL
furthermore gives also rise to mildly decreased levels of
LDL cholesterol (LDL-C), which originates fromVLDL.
Recently, the first Caucasian family was described with
partial CETP deficiency due to a novel splice site
mutation in the CETP gene.
PLTP is responsible for the majority of phospholipid
transfer activity in human plasma. Specifically, it
transfers surface phospholipids from VLDL to HDL
upon lipolysis of triglycerides present in VLDL. The
exact mechanism by which PLTP exerts its activity is
yet unknown. The best indications for an important role
in lipid metabolism have been gained from knockout
experiments in mice, which show severe reduction of
plasma levels of HDL-C and apoA-I. This is most likely
the result of increased catabolism of HDL particles that
are small in size as a result of phospholipid depletion. In
addition to the maintenance of normal plasma HDL-C
and apoA-I concentration, PLTP is also involved in a
process called HDL conversion. Shortly summarized,
this cascade of processes leads to fusion of HDLparticles into larger particles, with a concomitant
release of lipid-poor apoA-I. This newly formed lipid-
poor apoA-I is a pivotal particle in the uptake of free
cholesterol from peripheral cells via efflux n through
ABCA1. This is a potentially antiatherogenic function
of PLTP, but – surprisingly – overexpression of human
PLTP in mice results in increased susceptibility for diet-
induced atherosclerosis and a reduction of plasma
HDL-C, again due to hypercatabolism of apoA-I. At
present, no reports exist on genetic PLTP deficiency in
humans. Therefore, any hypothesis on the relevance of
PLTP activity for human lipid metabolism remains to be
confirmed. When it comes to humans, plasma PLTP
activity is increased in insulin-resistant individuals with
high plasma triglycerides and low HDL-C, as well as in
patients with diabetes mellitus. In patients with type
2 diabetes, PLTP activity is positively associated with
intima-media thickness, which is a surrogate measure
for the risk of atherosclerotic disease. In addition,
elevated PLTP activity is decreased by statin treatment.
Drugs
Plasma HDL-C concentration is negatively associated
with occurrence of cardiovascular disease, independent
of age, gender, LDL-C and other established risk
factors. Consequently, there is great interest for
pharmacological interventions to raise HDL-C. Among
the drugs that are currently available, statins, fibrates
and nicotinic acid exert such an increasing effect on
plasma HDL-C concentrations. These drugs, however,
are limited in their HDL-C raising efficacy (statins:
+3% to +9%, fibrates: +0% to +11%, nicotinic acid:
+7% to +23%) or exhibit significant side effects
(nicotinic acid: flushes). The high levels of HDL-C
observed in case of CETP deficiency have led to the
development of strategies to raise HDL-C by inhibition
of CETP activity in humans. Two such strategies are
currently in advanced stage of development, i.e.,
vaccine-induced inhibition and inhibition of CETP
activity through small-molecule compounds. Among
these, the latter has attracted most attention. The effects
of CETP inhibition through small-molecule compounds
parallel those observed in genetic CETP deficient
subjects to a large extent: increase of plasma HDL-C
and apoA-I concentration, with the occurrence of large
sized HDL particles due to cholesteryl ester enrichment.
In case of potent CETP inhibition, plasma levels of
LDL-C and apoB are also decreased. With respect to the
effects on cardiovascular disease exerted by these
lipoprotein changes, data from epidemiological studies
might justify optimism. However, clinical trials asses-
sing the consequences of CETP inhibition on surrogate
and clinical cardiovascular endpoints are required.
One such trial has recently been terminated due to an
increased number of lethal cardiovascular events
occurring in the CETP-inhibition group. At themoment,
696 Lipidationit remains to be established whether this relates to
intrinsic characteristics of the study drug or to the
mechanism of CETP-inhibition in general.
Due to the absence of human models for PLTP
deficiency, our knowledge about the relevance of
plasma PLTP activity for human lipid metabolism is
still incomplete. No investigational drugs are available
that specifically target the activity of this protein.
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cron and VLDL triglycerides.
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Synonyms
Lipid metabolism; Cholesterol metabolism
Definition
▶Lipoprotein metabolism is the process by which hy-
drophobic lipids, namely triglycerides and cholesterol,
are transported within the interstitial fluid and plasma. It
includes the transport of energy in the form of
triglycerides from intestine and liver to muscles and
adipose, as well as the transport of cholesterol both from
intestine and liver to peripheral tissues, as well as from
peripheral tissues back to the liver.
Basic Mechanisms
Lipoproteins are largemacromolecular complexes,which
transport triglycerides and cholesterol within the blood.
Triglycerides are a key component of energy transport
and metabolism, and cholesterol is an essential com-
ponent of all cells and required for steroidogenesis.
The structure of lipoproteins is a hydrophobic neutral
lipid core consisting of triglycerides and cholesteryl
esters, surrounded by amphipathic phospholipids and
specialized proteins known as ▶apolipoproteins. Phos-
pholipids serve to permit interaction with the aqueous
environment, and apolipoproteins are required for the
structural integrity of lipoproteins and direct their meta-
bolic interactions with enzymes, lipid transport proteins,
and cell surface receptors. The five major families of
lipoproteins are ▶chylomicrons, ▶very-low-density
lipoproteins (VLDL), ▶intermediate-density lipopro-
teins (IDL), low-density lipoproteins (LDL), and
▶high-density lipoproteins (HDL). Chylomicrons are
the largest andmost lipid-rich lipoproteins, whereasHDL
are the smallest lipoproteins and contain the least amount
of lipid. In the exogenous pathway of lipid transport
(Fig. 1), dietary fat and cholesterol are absorbed by
intestinal enterocytes and incorporated into chylomi-
crons, which contain the major structural apolipoprotein
B-48.Chylomicrons are initially secreted into lymph thus
bypassing the hepatic first pass effect. Once they gain
entry into the systemic circulation they bind to▶lipopro-
tein lipase (LPL) on the luminal surface of the capillary
endothelium of tissues (▶endothelial lipase), especially
muscle and adipose tissue. The LPL hydrolyzes the
triglycerides (apolipoprotein C-II on the chylomicron
surface is a required cofactor for LPL). The free fatty
Lipoprotein Metabolism. Figure 1 Exogenous pathway of lipoprotein metabolism.
Lipoprotein Metabolism. Figure 2 Endogenous
pathway of lipoprotein metabolism.
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Lacids enter the tissue to be used for energy (muscle) or
storage (adipose) and the triglyceride-depleted chylomi-
cron remnant (CMR) is released. CMRs are taken up by
the liver by binding of apolipoprotein E to the LDL
receptor and the LDL receptor-related protein (LRP). In
the endogenous pathway of lipid transport (Fig. 2), the
liver synthesizes triglycerides and cholesteryl esters and
packages them into VLDL, which contain the major
structural apolipoprotein B-100. VLDLs are hydrolyzed
by LPL to form intermediate density lipoproteins (IDL).
IDL can be taken up by the liver via binding of
apolipoprotein E to the LDL receptor or LRP. Alterna-
tively, the triglyceride and phospholipid in IDL can be
hydrolyzed by ▶hepatic lipase (HL) within the hepatic
sinusoids to form LDL. LDL can be taken up by
peripheral cells or by the liver by the binding of
apolipoprotein B-100 to the LDL receptor.
The pathways of HDL metabolism and reverse
cholesterol transport are complex (Fig. 3, [1]). HDL
and its major apolipoprotein apoA-I are synthesized
by both the intestine and the liver. A second majorHDL protein apoA-II is made only by the liver. Nascent
HDL interacts with peripheral cells to facilitate the
removal of excess free cholesterol through a process
that is facilitated by the cellular protein ATP-binding
cassette protein A1 (ABCA1). Some of the acquired
free cholesterol is esterified to cholesteryl ester on the
HDL particle by the action of the enzyme ▶lecithin-
cholesterol acyltransferase (LCAT) and the nascent
HDL particle becomes the larger HDL3. HDL acquires
further cholesteryl ester by continued LCAT action and
eventually becomes the even larger HDL2. HDL2 can
selectively transfer both cholesteryl ester and free
cholesterol to the liver via an HDL receptor in the liver
called scavenger receptor BI (SR-BI). Cholesteryl
esters can also be transferred from HDL2 to apoB-
containing lipoproteins such as VLDL and LDL via the
action of the▶cholesteryl ester transfer protein (CETP)
and then returned to the liver by hepatic uptake of LDL.
HDL2 triglycerides and phospholipids can be hydro-
lyzed by HL and endothelial lipase (EL) to remodel it to
HDL3. Cholesterol derived fromHDL contributes to the
hepatic cholesterol pool used for bile acid synthesis and
the cholesterol is eventually excreted into the bile
and feces as bile acid or free cholesterol.
Disorders of lipoprotein metabolism involve pertur-
bations which cause elevation of triglycerides and/or
cholesterol, reduction of HDL-C, or alteration of pro-
perties of lipoproteins, such as their size or composi-
tion. These perturbations can be genetic (primary) or
occur as a result of other diseases, conditions, or drugs
(secondary). Some of the most important secondary
disorders include hypothyroidism, diabetes mellitus,
renal disease, and alcohol use. Hypothyroidism causes
elevated LDL-C levels due primarily to downregulation
of the LDL receptor. Insulin-resistance and type
2 diabetes mellitus result in impaired capacity to
catabolize chylomicrons and VLDL, as well as excess
hepatic triglyceride and VLDL production. Chronic
kidney disease, including but not limited to end-stage
Lipoprotein Metabolism. Figure 3 HDL metabolism and reverse cholesterol transport.
698 Lipoprotein Metabolismrenal disease, is associated with moderate hypertrigly-
ceridemia due to a defect in triglyceride lipolysis and
remnant clearance. Nephrotic syndrome is associated
with a more pronounced hyperlipidemia involving both
elevated triglycerides and cholesterol due to hepatic
overproduction of VLDL. Alcohol consumption inhi-
bits oxidation of free fatty acids by the liver, which
stimulates hepatic triglyceride synthesis and secretion
of VLDL; the usual lipoprotein pattern associated with
alcohol consumption is moderate hypertriglyceridemia.
Inherited disorders of lipoprotein metabolism have
provided important insights into the molecular regulation
of lipoprotein metabolism in humans. The familial
hyperchylomicronemia syndrome (FCS) (also known as
Type I hyperlipoproteinemia), characterized by severely
elevated triglycerides, is caused by genetic deficiency of
either ▶LPL or apoC-II, demonstrating the essential
nature of each of these protein for the hydrolysis of
chylomicron triglycerides. Familial dysbetalipoprotei-
nemia (FD) (also known as Type III hyperlipoproteine-
mia), characterized by elevation in apoB-containing
lipoprotein remnant particles containing both triglycer-
ides and cholesterol, is caused by specific mutations in
the gene for apolipoprotein E (apoE), most commonly
homozygosity for the relatively common apoE2 variant.
This proved the essential nature of apoE for normal
clearance of lipoprotein remnants by the liver. Familial
hypercholesterolemia (FH) (also known as Type IIa
hyperlipoproteinemia), characterized by elevation in
LDL cholesterol, is caused by loss-of-function muta-
tions in the LDL receptor. Homozygotes are more
severely affected than heterozygotes, demonstrating the
gene dose effect of the LDL receptor on LDL-C levels.
This disorder established the key role of the LDL
receptor in regulating plasma levels of LDL-C through
mediating uptake of LDLby the liver.Mutations in other
genes have been subsequently discovered to regulate
the hepatic expression of the LDL receptor and
thus influence plasma LDL-C levels. These includeloss-of-function mutations in the autosomal recessive
hypercholesterolemia (ARH) gene, a recessive trait, and
gain-of-function mutations in the proprotein convertase
subtilisin/kexin type 9 (PCSK9) gene, an autosomal
dominant trait. Sitosterolemia is caused by mutations in
one of two members of the adenosine triphosphate
(ATP)-binding cassette (ABC) transporter family,
ABCG5 and ABCG8, resulting in increased cholesterol
in the liver and secondary downregulation of the LDL
receptor. Finally, mutations in the receptor binding
region of apoB-100, the ligand for the LDL receptor, can
impair its binding to the LDL receptor and delay the
clearance of LDL, a condition known as familial
defective apoB-100 (FDB).
Genetic conditions causing low cholesterol have also
provided important insights and novel pharmacologic
targets. Abetalipoproteinemia is characterized by ab-
sence of plasma apoB-containing lipoproteins and is
caused by mutations in the gene encoding microsomal
triglyceride transfer protein (MTP), a protein that
transfers lipids to nascent chylomicrons and VLDL in
the intestine and liver, respectively. Familial hypobeta-
lipoproteinemia is characterized by markedly reduced
LDL-C and apoB levels and is caused by mutations in
apoB that generally result in premature truncation that
either reduce secretion and/or accelerate catabolism.
Finally, loss-of-function mutations in PCSK9 have been
shown to cause low LDL-C levels and substantial
lifetime protection from CHD. All three of these gene
products are targets for the development of new
therapies for reducing LDL-C levels.
Genetic disorders of HDL metabolism have also
resulted in greater understanding of the molecular
regulation of HDL metabolism. Nonsense or missense
mutations in apoA-I can result in substantially reduced
HDL-C levels due to rapid catabolism of structurally
abnormal or truncated apoA-I proteins. Tangier disease
is a rare autosomal codominant disorder characterized
by markedly low HDL-C and apoA-I levels and caused
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Lby mutations in the gene ABCA1. ABCA1 facilitates
efflux of cholesterol from cells to lipid-poor apoA-I,
and in its absence apoA-I is not appropriately lipidated
and is rapidly cleared from the circulation. LCAT
deficiency causes markedly low levels of HDL-C,
establishing the importance of cholesterol esterification
by LCAT in the maintenance of normal HDL metabo-
lism. Finally, CETP deficiency causes markedly
elevated levels of HDL-C, establishing the importance
of cholesteryl ester by CETP in the maintenance of
normal HDL metabolism. Again, all of these gene
products are targets of new HDL-based therapies.
Pharmacologic Relevance
LDL Cholesterol Reduction
Disorders of lipoprotein metabolism are important risk
factors for atherosclerotic vascular disease (ASCVD).
Thus the field of lipoprotein metabolism has been a
fertile area for the development of drugs that modulate
the levels of plasma lipoproteins. Intervention with
drugs to reduce ▶LDL cholesterol has been proven to
decrease the risk of cardiovascular events [2]. Interven-
tion with drugs to reduce triglycerides or raise HDL-C
has not yet been definitively proven to reduce
cardiovascular events. The early clinical trials for
LDL-C reduction utilized niacin, bile acid sequestrants,
and even the surgical approach of partial ileal bypass to
reduce serum cholesterol levels. However, the bulk of
the data supporting LDL-C reduction comes from the
clinical outcome trials with ▶HMG CoA-reductase
inhibitors (statins). Early studies focused on patients
with preexisting CHD, including the Scandinavian
Simvastatin Survival Study (4S), the Cholesterol and
Recurrent Events (CARE) study, and the Long-Term
Intervention with Pravastatin in Ischemic Disease
(LIPID) trial and established the efficacy of statin
therapy in reducing cardiovascular events in patients
with CHD. Early primary prevention trials included the
West of Scotland Coronary Prevention Study (WOS-
COPS) and the Air Force/Texas Coronary Atheroscle-
rosis Prevention Study (AFCAPS/TexCAPS) and
confirmed that the benefits of LDL cholesterol
reduction extend to the primary prevention setting.
Subsequent studies have expanded downward the range
of baseline LDL-C levels for which statin therapy is
beneficial as well as the target LDL that is effective [2],
and include the Heart Protection Study (HPS), the
Anglo-Scandinavian Cardiac Outcomes Trial Lipid-
lowering Arm (ASCOT-LLA), the Collaborative Ator-
vastatin Diabetes Study (CARDS), the Treat to New
Targets (TNT) trial, and the Pravastatin or Atorvastatin
Evaluation and Infection Therapy (PROVE-IT) study.
These studies strongly support the “lower is better”
approach to reducing LDL-C as applied to high-risk
patients.Thus drug therapy for LDL-C reduction is widely
used. Statins are the cornerstone of LDL-C reducing
drug therapy. By inhibiting cholesterol biosynthesis in
the liver, statins lead to increased hepatic LDL receptor
expression. There are six statins currently available:
lovastatin, pravastatin, simvastatin, fluvastatin, ator-
vastatin, and rosuvastatin. There is wide interindividual
variation in the initial response to a statin, but once a
patient is on a statin, the doubling of the statin dose
produces a very predictable 6% further reduction in
LDL-C. Some patients treated with statins develop
muscle fatigue or pain, and severe myopathy and
rhabdomyolysis have been reported. The risk of statin-
associated myopathy is increased by the administration
of drugs that interfere with the cytochrome P450
metabolism of statins [3]. Due to both inadequate
reduction of LDL-C in some patients as well as statin
intolerance in others, there is a clinical need for LDL-
reducing drug therapy beyond statins. The most
commonly used class is that of cholesterol absorption
inhibitors; currently ezetimibe is the only drug in
this class clinically available. Ezetimibe binds to and
inhibits the function of NPC1L1, a major cholesterol
transporter in the intestinal enterocyte responsible for
absorption of luminal cholesterol derived both from diet
as a well as from bile. The inhibition of intestinal
cholesterol absorption reduces hepatic cholesterol
content and results in upregulation of hepatic LDL
receptor expression. Ezetimibe at the 10 mg dose
reduces cholesterol absorption by about 60% and
reduces LDL-C levels by about 18% on average as
monotherapy, and to a similar extent when used in
combination with a statin. Ezetimibe is used in combi-
nation with statins to further reduce LDL-C levels and
in patients who are statin-intolerant. In some cases, a
third class of LDL-lowering drugs, bile acid seques-
trants, is needed. Bile acid sequestrants bind bile acids
in the intestine, prevent their reabsorption, and accele-
rate their loss in the feces. In order to maintain an
adequate bile acid pool, the liver diverts cholesterol to
bile acid synthesis, resulting in decreased hepatic
cholesterol and upregulation of hepatic LDL receptor
expression. Cholestyramine and colestipol are insoluble
resins that must be suspended in liquid and colesevalam
is available as large tablets, and relatively large amounts
of bile acid sequestrants must be used to achieve
effective LDL reduction.
Inability to achieve LDL-C goals with existing drug
therapy remains an important unmet medical need.
Advances in our understanding of the molecular
regulation of LDL metabolism have generated new
pharmacologic targets. These include the following: (i)
inhibition of squalene synthase, another important
enzyme in the cholesterol biosynthetic pathway; (ii)
inhibition of MTP, which reduces VLDL production
700 Lipoproteinsand has been shown to reduce LDL-C levels; (iii)
inhibition of apoB production using an antisense
oligonucleotide approach; (iv) inhibition of PCSK9
based on the persuasive genetic data reviewed above.
The data supporting reduction in triglycerides or
raising of HDL-C are much less abundant [4]. Fibrates
and nicotinic acid are the most effective drugs in
lowering TGs and raising HDL-C. Fibrates are agonists
of PPARα and aremost effective as triglyceride lowering
drugs, with modest effects in raising HDL-C. Fibrates
lower triglycerides by activating PPARα to stimulate
▶LPL (enhancing triglyceride hydrolysis) and reduce
hepatic apoC-III synthesis (enhancing clearance of TG-
rich lipoproteins). A limited number of clinical trials
with fibrates support the concept that they may reduce
cardiovascular risk, particularly in patients with the
phenotype of insulin-resistance. Increasingly, fibrates
are being used in combination with statins. Nicotinic
acid, or niacin, is a B-complex vitamin that in high doses
lowers triglycerides and raises HDL-C levels. Niacin
acutely reduces free fatty acid levels through inhibition
of adipocyte triglyceride lipolysis, an effect now
known to be mediated by the niacin receptor GPR109A,
a G protein coupled receptor primarily expressed on
adipocytes. Whether this mechanism accounts for the
triglyceride lowering andHDL-C raising associatedwith
niacin therapy is uncertain. The clinical use of niacin is
limited by prostaglandin-mediated cutaneous flushing
which is also mediated by GPR109A expressed on
dermal macrophages. Data that niacin reduces cardio-
vascular risk is limited, but are consistent with a
cardioprotective effect. Patients with combined hyper-
lipidemia may achieve their LDL-C goal with a statin
alone, but frequently have persistently elevated trigly-
cerides and often do not achieve their non-HDL-C goal.
In this situation, the addition of either niacin or a fibrate
to the statin can be highly effective in reducing the
triglycerides and non-HDL-C levels. The therapy of low
HDL-C is amajor unmetmedical need andnew therapies
designed to raise HDL-C levels or promote HDL
function are under active development [1].
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▶Low-Density Lipoprotein Receptor Gene FamilyLiposomesPhospholipid vesicles, uncoated or polyethylenglycol-
coated. They can be used to vehicle drugs, antibodies or
nucleic acids to target cells.5-Lipoxygenase5-lipoxygenase is the enzyme causing catalysis of
arachidonic acid into leukotriene A4.
▶LeukotrienesLipoxygenases▶LeukotrienesLithocholic Acid3α-Hydroxy-5β-cholanoic acid, a hepatotoxic and
cholestatic secondary bile acid, formed by bacterial
dehydroxylation of primary bile acids in the intestine.
▶Nuclear Receptor Regulation of Hepatic Cytochrome
P450 Enzymes
Local Anaesthetics 701Local AnaestheticsLocal Anaesthetics. Figure 1 Common structure of
local anaesthetics. A lipophilic moiety on the left, an
aliphatic spacer containing an ester or amide bond in the
middle and an amine group on the right are the typical
structural elements for local anaesthetic drugs.
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Local anaesthetics are drugs that reversibly interrupt
impulse propagation in peripheral nerves thus lead-
ing to autonomic nervous system blockade, analgesia,
anaesthesia and motor blockade in a desired area of
the organism.
Mechanism of Action
Impulse propagation in the▶peripheral nervous system
depends on the interplay between ion channels selective
to potassium and sodium. Briefly, few voltage insensi-
tive potassium channels allow diffusion of positively
charged potassium ions from the internal side of the
axon to the exterior. This leaves a negative charge at
the internal side that is called resting potential and
amounts to approximately −80 mV over the ▶axonal
membrane. Upon a small depolarisation of the
membrane, ▶voltage–gated Na+ channels open (acti-
vate) and conduct positively charged sodium ions from
the exterior to the interior of the axon that depolarises
the membrane to about +60 mV (action potential).
After a few milliseconds the channels close spon-
taneously (inactivation) terminating the action potential
and thus giving it an impulse like character. The action
potential spreads electrotonically toneighbouring sodium
channels that also open to produce an action potential.
In this way, the impulse is propagated along the nerve
to (afferent) or from (efferent) the central nervous system.
Local anaesthetics inhibit ionic current through voltage
gated sodium channels in a concentration dependent
and reversible manner therefore directly blocking the
impulse propagation process in either direction [1].
The interaction between the local anaesthetic molecule
and the sodium channel is complex. The binding affinity
is low for resting channels, but dramatically increases
when the channel is activated. Thus, at high stimulus
frequency sodiumcurrent block increases (use-dependent
block). Use-dependent block is not important for con-
duction block during local anaesthesia since very high
concentrations are reached locally producing complete
and sufficient block. However, when local anaesthetics
such as lidocaine are applied intravenously, lower sys-
temic concentrations may already induce use-dependent
block and thus reduce excitability in electrically active
cells. This mechanism is important for the successful
use of lidocaine as an antiarrhythmic or analgesic drug.The putative binding site for local anaesthetic mole-
cules at the sodium channel has been identified as two
amino acids in the sixth membrane-spanning segment
of domain IV [2]. This binding site is located directly
underneath the channel pore and can only be reached
from the internal side of the membrane. Because local
anaesthetics are applied exterior to the nerve fibre, they
have to penetrate the axonal membrane before they can
bind to the channel.
Besides sodium channels, other ion channels such
calcium- and potassium channels as well as certain
ligand-gated channels are affected by local anaesthetics.
However, this plays only a minor role for nerve block
but may have more impact on adverse effects induced
by systemical concentrations of these drugs.
Structure Activity Relation
Local anaesthetics comprise a lipophilic and a hydrophil-
ic portion separated by a connecting hydrocarbon chain
(Fig. 1). The hydrophilic group is mostly a tertiary amine
such as diethylamine; the lipophilic group is usually
an unsaturated aromatic ring such as xylidine or para-
aminobenzoic acid. The lipophilic portion is essential for
anaesthetic potency whereas the hydrophilic portion is
required for water solubility. Both groups are important
for binding the drug molecule to the sodium channel.
The connecting hydrocarbon chain usually contains an
ester or an amide, in rare cases also an ether, and separates
the lipophilic and hydrophilic portions of the molecule
in an ideal distance for binding to the channel. Local
anaesthetics are classified by the nature of this bond into
ester or amide local anaesthetics. This bond is also
important for metabolism of the drugs and to adverse
reactions such as allergic reactions. Clinically relevant
local anaesthetics have an efficacy of 100%, i.e. at high
concentrations they completely abolish the sodium
current. Their blocking potencies range from a few
micromolar to millimolar half-maximal blocking con-
centration and are highly dependent on lipid solubility.
To a smaller amount potency also depends on the
structure of the molecule and on the type of bonding
702 Local Anaesthetics(Table 1). Further determinants of blocking potency are
themembrane potential and the state inwhich the sodium
channel is in (resting, activated, inactivated). The tertiary









The ending “caine” stems from cocaine, the first clinically employed loca
the others are amides. Amide bonded local anaesthetics usually conta
drawings, the lipophilic portion of the molecule is depicted at the left, th
stereoisomeric drugs. Lipid solubility is given as the logarithm of the wanaesthetics a pKa of about eight so that a larger amount
of the drug is in the hydrophilic form when injected
into tissue with physiological pH. However, only the










1 0.5–1 1.92 236 9.1
8 2–3 3.73 264 8.6
2 1–2 2.26 234 8.2
2 1–2 2.11 220 7.9
2 1,5–2 1.95 246 7.9
6 3–5 2.90 274 8.2
8 4–6 3.41 288 8.2
l anaesthetic. Procaine and tetracaine are ester-linked substances,
in two i’s in their name, ester-bonded only one. In the structure
e amine at the right. The asterisk marks the chiral centre of the
ater:octanol partition coefficient, log(P).
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Laxonal membrane, which is required before binding to
the sodium channel can occur. In a very acidic envi-
ronment, like inflamed tissue, local anaesthetics are
highly protonated, therefore cannot penetrate the axonal
membrane and have little effect.
Toxicity
Local anaesthetics interferewith all voltage-gated sodium
channel isoforms in an organism and thus with all
electrically excitable cells in organs such as brain, heart
and muscle. The major unwanted effects of local
anaesthetics are thus disturbances of brain and heart
function occurring during systemically high concentra-
tions after overdosing or after accidental intra-vascular
injection. Cerebral convulsions, general anaesthesia as
well as dysrhythmias up to asystolic heart failure or
ventricular fibrillation are feared as rare but most harmful
complications. Other adverse effects can be allergic
reactions. This occurs especially with ester-bonded
local anaesthetics because their metabolism produces
para-aminobenzoic acid that may serve as a hapten.
As a special case, the local anaesthetic prilocaine is
metabolised to o-toluidine, which may induce methemo-
globinemia, especially in patients that have a glucose-6-
phosphatase deficiency. The ▶S-stereoisomers of the
piperidine local anaesthetics bupivacaine and ropivacaine
have now been introduced into clinical practise to reduce
side effects. Their blocking potencies are minimally
lower compared to their R-counterparts but their thera-
peutic index is wider.
Clinical Use
Local anaesthetics are mainly employed to induce
regional anaesthesia and analgesia to allow surgical
procedures in a desired region of the organism. Nerve
block result in autonomic nervous system blockade,
analgesia, anaesthesia and motor blockade. The patient
normally stays awake during surgical procedures under
regional anaesthesia, but regional anaesthesia can also
be combined with general anaesthesia to reduce the
requirement of narcotics and analgesic drugs. Local
anaesthetics have to be injected locally into the circum-
ference of a peripheral nerve, which gives sufficiently
high concentrations to achieve conduction block. Cer-
tain injection techniques and procedures such as single
nerve block as well as spinal,▶epidural, or intravenous
regional anaesthesia have evolved to achieve the
desired nerve block. It is also possible to place a
catheter adjacent to a nerve and continuously apply
local anaesthetics to receive long-term analgesia. Low
concentrations of lipophilic local anaesthetics may be
used for differential nerve block, i.e. only block of
sympathetic and nociceptive fibres whereas somatosen-
sory and motor fibres are less affected. Differential nerve
block for example is useful in labour analgesia or for
analgesia after surgical procedures of the extremities.After local anaesthetic injection, onset of nerve block
and duration depends mainly on lipid solubility and
on the region in where the drug is injected. In some
formulations adrenaline is added to prolong the block-
ing action by inducing regional vasoconstriction and
hereby reduce absorption and metabolisation.
The amide local anaesthetic lidocainemay also be used
as an antiarrhythmic for ventricular tachycardia and exra-
systoles after injection into the blood circulation. Drugs
with high lipid solubility such as bupivacaine cannot be
used for these purposes because their prolonged binding
to the channelmay induce dysrhythmias or asystolic heart
failure [3]. Systemically applied lidocaine has also been
used successfully in some cases of ▶neuropathic pain
syndromes [4]. Here, electrical activity in the peripheral
nervous system is reduced by used-dependent but
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▶PharmacogenomicsLocus CeruleusThe locus ceruleus is a structure located on the floor of
the fourth ventricle in the rostral pons. It contains more
than 50% of all noradrenergic neurons in the brain, and
projects to almost all areas of the central nervous system.
704 Long-Chain Fatty AcidsThe locus ceruleus is important for the regulation of
attentional states and autonomic nervous system acti-
vity. It has also been implicated in the autonomic and
stress-like effects of opiate withdrawal. A noradrenergic
pathway originating from the locus ceruleus which
descends into the spinal cord is part of the descending
inhibitory control system, which has an inhibitory effect
on nociceptive transmission in the dorsal horn.
Long-Chain Fatty AcidsLong-chain fatty acids (LCFAs) are aliphatic com-
pounds with a terminal carboxyl group and with a chain
length greater than 12 carbon atoms (e.g., lauric acid).
Very long-chain fatty acids are fatty acids with more
than 18 carbon atoms (e.g., stearic acid).
▶Fatty Acid Transport Proteins
Long-QT SyndromesLong-QT syndromes (LQTS) are potentially fatal
inherited cardiac arrhythmias characterized by pro-
longed or delayed ventricular repolarization, manifested
on the electrocardiogram as a prolongation of the QT
interval. LQTS can be caused bymutations of at least six
genes including KCNQ1 for LQT1, KCNH2 for LQT2,
SCN5A encoding a cardiac sodium channel for LQT3,
KCNE1 for LQT5 and MiRP1 for LQT6. LQT4 is
linked to the mutations located in chromosome 4q25–




Long-Term DepressionLong-term depression (LTD) is a synaptic plasticity
phenomenon that corresponds to a decrease in the syn-
aptic strength (decrease in the post-synaptic response
observed for the same stimulation of the pre-synapticterminals) observed after a specific stimulation of the
afferent fibres. This decreased response is still observed





Long-term potentiation (LTP) is a synaptic plasticity
phenomenon that corresponds to an increase in the
synaptic strength (increase in the post-synaptic
response observed for the same stimulation of the
presynaptic terminals) observed after a high frequency
stimulation (tetanus) of the afferent fibres. This
increased response is still observed hours and even
days after the tetanus. The phenomenon is often
observed at glutamatergic synapses and involves, in
most cases, the activation of the N-methyl D-aspartate





Low-density-lipoprotein-cholesterolLDL is the major carrier of cholesterol to the periphery
and supplies the cholesterol essential for the integrity of
nerve tissue, steroid hormone synthesis, and cell
membranes. The association between elevated plasma
cholesterol carried in LDL and the risk of coronary heart
disease has been well established. LDL is also
sometimes called the “bad” cholesterol.
▶Lipoprotein Metabolism
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Synonyms
Low-density lipoprotein receptor-related proteins; LRP
Definition
The low-density lipoprotein ( ▶LDL ) receptor gene
family encompasses a group of structurally related
endocytic receptors that are expressed in many
mammalian and nonmammalian cell types. The recep-
tors mediate cellular binding and uptake of a variety of
diverse macromolecules including lipoproteins and
lipid-carrier-complexes, proteases and protease inhibi-
tors, signaling factors, as well as viruses and toxins.
Gene family members play crucial roles in many
biological processes ranging from lipid homeostasis, to
signal transduction, to cell migration.
Basic Characteristics
Receptor-Mediated Endocytosis
Endocytic receptors are cell surface proteins that transport
macromolecules into cells through a process known as
receptor-mediated ▶endocytosis. I n t hi s p ro ce ss , a
receptor on the cell surface binds a specific ligand
from the extracellular space, internalizes via specialized
in-tucked regions of the plasma membrane called
clathrin-coated pits, and moves to an intracellular vesicle
(▶endosome) to discharge its cargo. From endosomal
compartments, ligands are further directed to lysosomes
for catabolism, while the unliganded receptor returns to
the cell surface to initiate the next round of endocytosis.
Endocytic receptors serve to regulate the concentration of
ligands in the extracellular space and to deliver them to
cells in need of these metabolites. Binding of some
ligands to endocytic receptor may also trigger intracellu-
lar signaling cascades involved in regulation of important
physiological processes such as embryonic patterning,
neuronal cell migration, or synaptic plasticity.
Structural Organization of the LDL Receptor
Gene Family
Much of our knowledge of the structure and function
of endocytic receptors is based on the analysis of the
LDL receptor gene family. Members of this extended
gene family can be found in a variety of species ranging
from roundworms to insects, to vertebrates. Ten recep-
tors exist in mammalian organisms, all of which share
common structural motifs required for receptor-mediatedendocytosis (Fi g. 1). Among other modules, their
extracellular domains are composed of clusters of
▶complement-type repeats, the site of ligand binding,
as well as β-propellers, essential for pH-dependent release
of ligands in endosomes. The cytoplasmic tails harbor
recognition sites for cytosolic adaptor proteins involved
in protein trafficking and signal transduction. All ecto-
domains share significant sequence similarity in linewith
the ability of the receptors to bind an overlapping
spectrum of ligands. In contrast, their cytoplasmic
domains are unique, indicating distinct cellular fates for
macromolecules internalized by individual receptors [1].
Functions of the LDL Receptor Gene Family
Transgenic animal models with spontaneous or induced
receptor gene defects have been instrumental in
elucidating the physiological roles of the LDL receptor
gene family. In addition, a number of human diseases
have been identified that are caused by sporadic or
inherited forms of receptor deficiency (Table 1).
LDL Receptor
The LDL receptor is the archetype receptor of the gene
family. It is the major endocytic receptor responsible for
cellular uptake of cholesterol-rich ▶lipoproteins from
the circulation and extracellular body fluids. It binds
lipoprotein particles that contain the ▶apolipoproteins
B-100 (APOB-100) or APOE, and mediates their
endocytic uptake. Particles internalized via the LDL
receptor are delivered to lysosomal degradation where
the apolipoproteins are broken down into amino acids
while the lipids are released into the cytosol for further
metabolism. The uptake of lipoproteins by the LDL
receptor has a dual role in lipid homeostasis. It delivers
cholesterol required for maintenance of cellular functions
(e.g., formation of membranes, synthesis of steroid
hormones, and bile acids), and it regulates the concentra-
tion of this lipid in the circulation. The importance of the
latter function is underscored by pathological abnormal-
ities observed in patientswith LDL receptor gene defects;
a syndrome designated familial hypercholesterolemia
(▶FH). In humanswith FH, lack of LDL receptor activity
results in massive increase in circulating LDL. The mean
plasma cholesterol levels are elevated approximately
twofold in individuals with heterozygous and fourfold in
patients with homozygous gene defects. As a conse-
quence of fulminate▶hypercholesterolemia, FH patients
suffer frompremature atherosclerosis and coronary artery
disease. To date more than 150 different mutations have
been identified in the human LDL receptor gene.
VLDLR and APOER2
Very low-density lipoprotein receptor (▶VLDLR) and
APOE receptor-2 (▶APOER2) are two gene family
members with redundant functions. They are expressed
in neurons of the developing brain and act as cell
Low-density Lipoprotein Receptor Gene Family. Figure 1 The LDL receptor gene family. The figure depicts
the structural organization of mammalian members of the LDL receptor gene family. APOER2 (apolipoprotein
E receptor 2); LDLR (low-density lipoprotein receptor); LRP (LDL receptor-related protein); MEGF7
(multiple epidermal growth factor repeat-containing protein 7); sorLA (sorting protein-related receptor); VLDLR
(very low-density lipoprotein receptor). Designations in brackets indicate alternative names for the respective
receptors.
Low-density Lipoprotein Receptor Gene Family. Table 1 Human diseases of the LDL receptor gene family










Autosomal recessive cerebellar hypoplasia (ataxia, mental
retardation)
LRP5 Loss-of-function (familial, autosomal
recessive)
Osteoporosis-pseudoglioma-syndrome (reduced bone mass)
Gain-of-function (familial, autosomal
dominant)
High-bone-mass trait (increased osteogenic activity)
LRP6 Missense mutation (familial,
autosomal dominant)
Autosomal dominant early coronary artery disease (hyperlipidemia,
hypertension, diabetes)





Donnai-Barrow syndrome (brain malformation, renal tubular
deficiency, diaphragmatic hernia)
SorLA Polymorphisms (sporadic) Late-onset Alzheimer’s disease
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Low-density Lipoprotein Receptor Gene Family 707surface receptor for ▶reelin , a secreted guidance factor
for newborn neurons that migrate to their proper
position in the laminating neocortex and cerebellum.
Binding of Reelin to VLDLR and APOER2 initiates an
intracellular signaling cascade that involves the cyto-
plasmic adaptor disabled-1 (▶ DAB1) bound to the
receptor tails, and that ultimately leads to reorganization
of the cytoskeleton and regulation of cell migration
( Fig. 2a ) [2]. Receptor gene defects in humans (Table 1)
and in animal models result in abnormal layering of
neurons in the brain, and in severe neuronal dysfunction
(cerebellar dysplasia, ataxia).
LRP5/6
These receptors are integral components of the ▶wi ng -
less (Wnt) signaling cascade by acting as coreceptors
to ▶frizzled. Simultaneous binding of Wnt ligands toLow-density Lipoprotein Receptor Gene Family. Figure
gene family. (a) The reelin signaling pathway in migrating n
cognate receptors VLDLR and APOER2. Binding induces 
activating SRC family tyrosine kinases (SFKs) that in turn p
activates phosphatidylinositol-3-kinase (PI3K) and protein 
synthase kinase 3β (GSK3β), resulting in reduced phospho
Lissencephaly 1 (LIS1) is another interaction partner of ph
multimeric protein complex that also regulates microtubule
Wnt signaling pathway, Wnt ligands bind to LRP5/6 and Fr
membrane-associated casein kinase 1γ (CK1γ). Phosphor
domain, preventing Axin-induced destruction of β-catenin.
high-mobility group protein TCF to induce target gene tranLRP5/6 and frizzled results in signal transduction through
the canonical Wnt signaling pathway (Fi g. 2 b) [3]. The
function of LRP6 seems most relevant for early
embryonic patterning events, as loss of receptor function
in fruit fly, Xe no pu s, and mouse causes aberrant pattern
formation and early embryonic lethality. In contrast,
LRP5 activity is mainly required for regulation of bone
formation as judged from loss-of-function and gain-of-
function syndromes in humans that result in low or high-
bone-mass traits, respectively (Ta b l e 1 ).
LRP4
LRP4 is another receptor of the LDL receptor gene family
involved in regulation of embryonic patterning, mainly
controlling formation of limb structures. Loss of receptor
activity in gene targeted mice or spontaneous mutation
in bovine cause abnormal limb development and 2 Signal transduction by members of the LDL receptor
eurons is initiated by binding of the guidance factor to its
clustering of DAB1 on the cytoplasmic receptor tails,
hosphorylate the adaptor. Phosphorylated DAB1
kinase B (PKB). PKB inhibits the activity of glycogen
rylation of Tau (τ) and stabilization of microtubules.
osphorylated DAB1. It associates with α-subunits to a
dynamics (modified from [2]). (b) As part of the canonical
izzled resulting in phosphorylation of the LRP5/6 tail by
ylation recruits scaffold protein Axin to the LRP tail
Stabilized β-catenin enters the nucleus to interact with
scription.
L
708 Low-density Lipoprotein Receptor-related Proteinspolysyndactyly. The molecular mechanisms of LRP4
actions remain unclear at present, but may also involve
signaling through embryonic morphogen pathways.
LRP1 and LRP1B
In hepatocytes, LRP1 serves as backup pathway to the
LDL receptor in hepatic clearance of ▶chylomicron
remnants , lipoproteins that transport dietary lipids from
the intestine to the liver. In vascular smooth muscle
cells, LRP1 likely acts as signaling receptor that
suppresses the activity of the platelet-derived growth
factor ( ▶PDGF) receptor. Loss of local LRP1 expres-
sion in mouse models causes enhanced activation of the
PDGF receptor pathway, resulting in smooth muscle
cell proliferation and in marked susceptibility to
atherosclerotic lesion formation [4]. LRP1B is also
known as LRP-DIT (deleted-in-tumors) because of its
original description as a gene frequently inactivated
in lung cancer cell lines. A possible role as tumor
suppressor gene remains yet to be established. LRP1B
may share some functional redundancy with LRP1 as
suggested from the close sequence similarity and
overlap in expression pattern of both receptors.
LRP2
LRP2 (megalin, gp330) is the largest member of the
LDL receptor gene family. Inherited Lrp2 gene defects
are the cause of Donnai-Barrow syndrome, character-
ized by brain malformation, renal dysfunction, and
diaphragmatic hernia. Rather than acting as lipoprotein
receptor such as the LDL receptor and LRP1, LRP2
functions as endocytic receptor for cellular uptake of
lipophilic vitamins and steroid hormones bound to
plasma carrier proteins [1]. Most notably, a role for the
receptor in retrieval of filtered 25-OH vitamin D3 bound
to the vitamin D binding protein ( ▶DBP ) from the
glomerular filtrate is appreciated. Renal uptake of
vitamin/DBP complexes prevents uncontrolled urinary
loss of this essential metabolite and it delivers to renal
proximal tubular cells the precursor for conversion into
1,25-(OH)2 vitamin D3, the active hormone that controls
systemic calcium and bone metabolism. Loss of receptor
function results in excessive urinary excretion of
vitamin D3 metabolites, and consequently, in vitamin
D deficiency and osteomalacia (softening of the bones).
SorLA
SorLA is a chimeric receptor that harbors protein
modules not present in other members of the LDL
receptor gene family ( Fig. 1). As well as acting as
endocytic receptor for extracellular ligands (such as
PDGF), sorLA also regulates the intracellular traffick-
ing of target proteins between secretory and endocytic
compartments. In particular, the receptor acts as sorting
receptor for the amyloid precursor protein (▶ APP), the
etiologic agent in ▶Alzheimer ’s disease. In neurons,
SorLA directs APP into intracellular compartments lessfavorable for proteolytic processing, thereby impairing
breakdown of APP to the amyloid- β peptide, the
principle component of senile plaques (a hallmark of
Alzheimer ’s disease). Polymorphisms in the human
SorLA gene are among the most important genetic risk
factors of late-onset Alzheimer ’s disease, likely by
determining the expression levels of this protective
factor in the brain of individuals [5].
Drugs
Currently no drugs directly modulating the LDL
receptor family are known. The possible use of drugs
targeting the LDL receptor family or downstream
signaling proteins may be derived from Table 1.
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LRPL▶Low-Density Lipoprotein Receptor Gene Family
LRP5 and LRP6LRP5 and 6 are closely related genes in humans and
mice that are structurally distinct from other LRP family
members. A single Drosophila ortholog exists and is
called arrow. The proteins are single-pass transmem-
brane receptors with an extracellular domain compris-
ing four amino-terminal epidermal growth factor
(EGF)-like repeats and three low density lipoprotein
(LDL) receptor type A repeats. They have a relatively
short proline-rich intracellular domain. Genetic evi-
dence in Drosophila as well as loss-of-function and
overexpression evidence in vertebrates support the
conclusion that arrow and LRP5/6 are essential
coreceptors with the Fz proteins for Wnt/β-catenin-
dependent signaling.
▶Wnt Signaling
▶Low-Density Lipoprotein Receptos Gene Family
LTD▶Long Term DepressionLTP▶Long Term Potentiation
Luteinizing Hormone▶Contraceptives
LymphangiogenesisLymphangiogenesis is the growth of lymphatic vessels,
which is critically controlled by the interaction of
VEGF-C and VEGF-D with the receptor VEGF-R3 on
lymphatic endothelial cells.
▶Angiogenesis and Vascular Morphogenesis
LymphocytesLymphocytes are specialized white blood cells that play
a crucial role in an immune response.They can be T
lymphocytes, which can directly target and destroy
defective cells, or B lymphocytes, which produce
antibodies directed against specific antigens. Both T
and B lymphocytes produce a variety of cytokines to




710 Lysine Acetylation of HistonesLysine Acetylation of Histones▶Histone Acetylation
Lysipressin▶Vasopressin/Oxytocin
Lysolipid Mediators▶Lysophospholipids
Lysophosphatidic AcidLysophosphatidic acid (LPA) is the prototype of a group
of bioactive lysophospholipids that act on specific






Potential signaling phospholipid derived from phos-
phatidylcholine by phospholipase action. No receptors
known.
▶Proton-Sensing GPCRs
▶LysophospholipidsLysophospholipidsDAGMAR MEYER ZU HERINGDORF






Lysophospholipids are small bioactive lipid molecules
characterized by a single carbon chain and a polar head
group. Two subgroups can be distinguished: molecules
containing the sphingoid base backbone (lysosphingo-
lipids) and molecules containing the glycerol backbone
(lysoglycerophospholipids). The lysolipid structure
renders these lipids more hydrophilic and versatile
than their corresponding phospholipids. Lysophospho-
lipids act as extracellular mediators activating specific
▶G-protein-coupled receptors (GPCRs), although some
of them additionally play a role in intracellular signal
transduction. ▶Sphingosine-1-phosphate (S1P) and
▶lysophosphatidic acid (LPA) have been characterized
in greatest detail so far, and the concept of lysopho-
spholipids as a group of mediators is supported by the
high homology between S1P- andLPA-specific GPCRs.
Other, less well characterized lysophospholipids are
sphingosylphosphorylcholine (SPC), lysophosphatidyl-
choline (LPC), psychosine (galactosylsphingosine) and
glucopsychosine (glucosylsphingosine); the latter two
are lacking a phosphate group. Lysophospholipids are
auto- or paracrine regulators of cell growth and survival,
migration and chemotaxis, cytoskeletal architecture,
cell–cell-contacts and adhesion, Ca2+ homoeostasis and
Ca2+-dependent functions. By regulating these cellular
functions, lysophospholipids play a role in angiogene-
sis, lymphocyte trafficking, development of the nervous
system, cancer growth andmetastasis, inflammation and
arteriosclerosis. Relatives of the lysophospholipid
family are platelet-activating factor and the ▶endocan-




S1P is formed from sphingosine by ▶sphingosine
kinases (SphKs). Degradation of S1P occurs either
reversibly by lipid phosphate phosphohydrolases
(LPPs) and S1P phosphatases (SPPs), or irreversibly
by S1P lyase (SPL) (Fig. 1). The localization of S1P
production is highly important since S1P plays a role













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































712 Lysophospholipidssecond messenger (Fig. 1). Intracellular formation of
S1P by SphKs is regulated by many diverse stimuli,
among them GPCR agonists, ▶growth factors, ▶cyto-
kines or depolarization. Some stimuli induce a
translocation of SphK1 from the cytosol to the plasma
membrane, which appears to enable S1P secretion and
so-called “inside-out signalling”. Many cell types
including mast cells and tumour cells can release S1P.
ATP-binding cassette (ABC) transporters have shown
to be involved in this process. S1P is furthermore stored
in platelets and released upon platelet activation.
Accordingly, it has been found in serum in higher
concentrations (0.5–0.8 μM) than in plasma (0.2–
0.4 μM). Plasma S1P is bound to albumin and
▶lipoproteins, mainly high-density lipoproteins
(HDL). Tissue S1P levels are significantly lower, and
thus there is a plasma/tissue S1P gradient.
LPA, i.e. monoacyl-glycerol-3-phosphate, can be
formed and degraded by multiple metabolic pathways
(Fig. 1). Depending on the precursor molecule and
respective pathway, the fatty acid chain in LPA differs in
length, degree of saturation and position (sn-1 or sn-2),









S1P2 Ubiquitous Gi/o, Gq,
G12/13





S1P5 Brain, white matter
tracts
Gi/o, G12
LPA1 LPA Ubiquitous Gi/o, Gq,
G12/13
LPA2 Ubiquitous Gi/o, Gq,
G12/13









activity S1P or SPC
Meiotic arrest of ro
neurons
OGR1 SPC Proton Inhibition of prolife
GPR4 SPC, LPC Migration, angioge
G2A LPC, SPC Migration, apoptos
TDAG8 Psychosine Formation of multanalogs with ether-bound alkyl or alkenyl chains are
quantitatively less abundant than those with ester-
bound acyl chains. Extracellular LPA is generated to a
large part by a lysophospholipase D named▶autotaxin.
Autotaxin is an extracellular enzyme that acts as
autocrine motility factor of tumour cells. LPA produc-
tion by autotaxin is essential for embryonic develop-
ment in mice and apparently contributes most of LPA
in plasma. Alternatively, LPA can be produced from
surface-exposed phosphatidic acid by phosphatidic
acid-selective PLA1 or secretory type-II PLA2. Like
S1P, LPA occurs in plasma (200 nM), is formed
during coagulation, and present in serum in micromolar
concentrations. Differences in the fatty acid composi-
tion of plasma- and serum-LPA suggest that the sources
of these LPA pools were different. LPA is produced
by many cell types, e.g. fibroblasts, adipocytes and
tumour cells.
Lysophospholipid Receptors
An overview of lysophospholipid GPCR is presented
in Table 1. Presently best characterized are the recep-
tors of the endothelial differentiation gene (EDG)olipid receptors
g Main biological effects
Migration ↑, proliferation, survival, cell–cell-contacts,
angiogenesis, lymphocyte trafficking
Migration ↓, vascular development, differentiation of
vascular smooth muscle cells
Heart rate ↓, vascular development, NO-dependent
vasorelaxation
/13 Proliferation and cytokine secretion in T-cells ↓
/13 Proliferation, cell rounding
Proliferation, survival, neurite retraction, brain devel-
opment
Proliferation, survival
Implantation and embryo spacing in mice
Main biological effects
tion, neurite retraction
dent oocytes, increase in synaptic contacts in rat cortical
ration, osteoclastogenesis
nesis, impairment of endothelial barrier function
is, suppression of autoimmunity
inuclear cells, apoptosis
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Lfamily, S1P1–5 and LPA1–3. They had originally been
named after EDG-1, now S1P1, which was detected in
1990 as an orphan GPCR upregulated during the
differentiation of endothelial cells. According to an
IUPHAR committee, these receptors are now named
after the primary natural ligand and numbered in order
of identification. S1P1–3 and LPA1–3 are widely
expressed and often found co-expressed within a single
cell type. S1P4 is predominantly expressed in lymphatic
and haematopoietic tissues and S1P5 in brain white
matter and skin. The EDG family receptors couple via
Gi/o, Gq/11 and G12/13 proteins to inhibition of
▶adenylyl cyclase, stimulation of phospholipase C
and increase in [Ca2+]i, stimulation or inhibition of
▶mitogen-activated protein kinases (ERK, JNK and
p38) and cell growth, activation of Akt and survival,
activation or inhibition of Rho and Rac and rearrange-
ment of the cytoskeleton, and finally stimulation or
inhibition of cell migration (for details, see Biological
Actions).
Much less is known about other lysophospholipid
receptors. LPA4 and LPA5 couple via Gs to activation
of adenylyl cyclase. GPR3, GPR6 and GPR12 have a
high constitutive activity, thereby stimulating adenylyl
cyclase, but appear to be further activated by S1P and/
or SPC. GPR6 and GPR12 are strongly expressed in
mouse brain, and SPC increased synaptic contacts in
GPR12-expressing embryonic cortical neurons. GPR3
and GPR12 are expressed in mouse oocytes and
mediate a signal that maintains the oocytes in meiotic
arrest, a process that is dependent on high cAMP
levels. A role for lipid ligands in meiotic arrest is likelyLysophospholipids. Figure 2 Functional roles of S1P ansince spontaneous in vitromaturation of rodent oocytes
was delayed by SPC and S1P.
Another group of putative lysophospholipid GPCR is
highly controversial. OGR1, GPR4, G2A and TDAG8
form a cluster of homologous GPCRs that are candidate
high-affinity receptors for SPC, LPC and psychosine
(Table 1). SPC and LPC are the phosphocholine-
containing analogs of S1P and LPA, respectively. Both
lipids are normal constituents of plasma and serum.
SPC acts also as a low-affinity or partial agonist at
S1P1–5. Contradictory studies have shown that the
receptors of the OGR1 cluster can be regulated by
lysophospholipids and/or by protons. Recent studies
revealed that OGR1 was strongly induced during
differentiation of bone marrow mononuclear cells into
osteoclasts, and knockdown of OGR1 attenuated
osteoclastogenesis. Endogenous GPR4 was required
for SPC-stimulated migration of endothelial cells and
endothelial tube formation. G2A and TDAG8 appear to
play a functional role in migration and apoptosis of
immune cells.
Finally, it has to be mentioned that LPA also has an
intracellular target site, which is the nuclear transcrip-
tion factor, peroxisome proliferator-activated receptor-γ
(PPARγ). LPA competes for thiazolidinedione binding
and activates PPARγ-dependent gene transcription.
Thereby, LPA induced neointima formation in a rat
carotid artery model.
Biological Actions
Cellular responses to S1P and LPA can be classified
as growth-related (stimulation of cell proliferation andd LPA.
714 Lysophospholipidssurvival, protection from apoptosis), cytoskeleton-
dependent (shape change, migration, adhesion, che-
motaxis) and Ca2+-dependent (contraction, secretion).
Some cellular responses are regulated in an opposite
manner by different receptors. For example, the S1P1
receptor mediates cell migration and chemotaxis,
thereby regulating for example angiogenesis and
lymphocyte trafficking. Growth factors such as plate-
let-derived growth factor need the S1P1 receptor for
signalling migration. On the contrary, this must be “and
inhibits migration”. S1P2 promotes cellular stress fibre
formation and inhibits migration. Furthermore, the
S1P1 receptor does not increase [Ca
2+]i but rather
inhibits [Ca2+]i increases by other agonists, while S1P2
and S1P3 mediate [Ca
2+]i increases in response to S1P.
S1P is an important mediator in the cardiovascular
system (Fig. 2). S1P stimulates proliferation, survival
andmigration of endothelial cells and induces formation
of adherens junction assembly, decrease in vascular
permeability and differentiation of endothelial cells into
capillary-like networks. Expression of the S1P1 receptor
within endothelial cells is required for vasculogensis.
Mice lacking this receptor die during embryonic
development from haemorrhages caused by a failure
of pericytes to migrate around newly formed capillaries.
S1P andLPA induce smoothmuscle cell contraction and
can cause vasoconstriction. S1P, via endothelial S1P3
receptors, can also cause NO-dependent vasorelaxation.
A lack of the S1P2 receptor results in profound deafness
in mice, apparently because the cochlear spiral artery
does not appropriately contract in the absence of S1P2.
The S1P3 receptor mediates IK(ACh) activation in atrial
myocytes, leading to bradycardia. However, systemic
cardiovascular parameters such as blood pressure or
heart rate are marginally affected by intravenous S1P,
consistent with a role of S1P as a local rather than
systemic mediator. The importance of LPA in vascular
development is illustrated by the phenotype of autotaxin
deficiency, which is characterized by vascular defects
early in development. LPA promotes surface expression
of leukocyte adhesion molecules in endothelial cells. In
contrast to S1P, LPA enhances vascular permeability. Of
the two platelet-derived lysophospholipids, LPA but not
S1P stimulates platelet aggregation. S1P, LPA and other
lysolipids have been detected in lipoproteins and play a
role in atherosclerosis. The major part of lipoprotein-
bound S1P is associated with HDL, and many of HDL’s
beneficial vascular effects are mediated by S1P and
S1P-GPCR. In contrast, LPA is produced during
mild oxidation of low-density lipoproteins (LDL) and
accumulates in atherosclerotic plaques where it acts
proinflammatory and promotes thrombus formation.
The S1P1 receptor and the gradient between lym-
phatic tissue (low S1P levels) and plasma (high
S1P levels) are essential for lymphocyte traffick-
ing. Deletion of S1P1, as well as pharmacologicaldownregulation of S1P1 (see Drugs), inhibit lympho-
cyte emigration from lymphatic tissues. Inhibition of
S1P lyase leads to elevated S1P tissue levels and also to
lymphopenia. It appears likely that the S1P1 receptor on
the lymphocyte surface senses the S1P gradient and
mediates lymphocyte trafficking.
LPA receptors play an important role in the nervous
system (Fig. 2). The LPA1 receptor was originally
cloned from cerebral cortical neuroblasts and is highly
expressed in the neurogenic ventricular zone of the
embryonic cerebral cortex. In the adult nervous system,
it is predominantly found in myelinating cells, i.e.
oligodendrocytes and Schwann cells. Schwann cell
morphology, adhesion and survival are regulated by
LPA. LPA1 and LPA2 receptors mediate neuronal cell
rounding and neurite retraction, while LPA3 appears to
stimulate neurite outgrowth. Deletion of the LPA1
receptor in mice caused 50% neonatal lethality. The
surviving pups had a reduced size, craniofacial dy-
smorphism and impaired suckling behaviour. The defect
in suckling behaviour caused malnutrition of the pups,
leading to growth retardation and death, and was
attributed to a defective olfaction. Deletion of LPA2 in
mice did not lead to obvious defects, while LPA3
deficiency was accompanied by 50% reduced litter
sizes. This was caused by downregulation of cyclooxy-
genase-2 (▶cyclooxygenases) in LPA3-deficient uteri
during preimplantation, which delayed implantation
and disturbed embryo spacing. The mice that were born
were grossly normal.
Both S1P and LPA stimulate proliferation and
migration of fibroblasts, while they inhibit proliferation
and induce migration and differentiation of keratino-
cytes. LPA promotes wound healing in vivo. Thus, S1P
and LPA interact in tissue repair. Many other tissues are
responsive to S1P or LPA, including the respiratory
tract (contraction of airway smooth muscle cells and
cytokine release by S1P), kidney (diuresis by S1P),
adipose tissue (preadipocyte proliferation by LPA), and
others. Finally, S1P and LPA promote tumour cell
growth, chemoresistance and metastasis (Fig. 2). The
two mediators are produced by several tumour cells and
occur for example in malignant ascites. The antiapop-
totic action of S1P and LPA may protect the cells from
chemotherapy or radiation. Furthermore, S1P and LPA
stimulate tumour cell motility and invasiveness,
although it has to be noted that motility of certain
cancer cells (e.g. melanoma cells) is inhibited by S1P.
S1P might also play a role in tumour angiogenesis. Its
importance for tumour progression is further illustrated
by the antitumour activity of SphK inhibitors and an
anti-S1P antibody (see Drugs).
In summary, the lysophospholipids are local media-
tors that regulate development, tissue regeneration and




In the field of S1P pharmacology, there is currently a
novel immunosuppressive (▶immunosuppressive
agents) in clinical development for multiple sclerosis.
FTY720 is a prodrug that, after being phosphorylated,
acts as an agonist with low nanomolar affinity on S1P1,
S1P3, S1P4 and S1P5, but not on S1P2 receptors. SphK2
is required for effective phosphorylation of FTY720
in vivo. The immunosuppressive action of FTY720 is
caused basically by activation and subsequent internali-
zation of the S1P1 receptor, which needs to be expressed
on the lymphocyte surface to enable sensing of the
plasma/tissue S1P gradient and to promote emigration
of lymphocytes from lymphatic tissues. Since FTY720
does not generally impair T- and B-cell proliferation
and functions, it presents a novel mode of immunosup-
pressive action, which might be useful in multiple
sclerosis as well as transplantation or autoimmune
diabetes. Activation of S1P receptor subtypes other
than S1P1 causes further, desired and undesired effects.
For example, the bradycardia that occurs during the
first days of FTY720 treatment is mediated by activa-
tion of S1P3. Animal models show further effects of
FTY720: it reduced the damage caused by ischemia-
reperfusion in liver and kidney, inhibited angiogenesis,
impeded tumour growth in amousemodel of melanoma,
induced endothelial NO synthase activation and vaso-
dilatation (via S1P3) and reduced vascular permeability
in vivo.
Other compounds acting on S1P-GPCR are only in the
experimental stage. Several specific S1P1 agonists have
been described. SEW2871, that has been identified by
high-throughput screening and lacks a phosphate group,
induces lymphopenia in mice (in agreement with the role
of S1P1 in lymphocyte trafficking) but no bradycardia (in
agreement with a lack of an effect on S1P3). KRP-203
needs to be phosphorylated, like FTY720, but then
activates specifically S1P1 and produces effects similar to
those of SEW2871. Interestingly, the S1P1 receptor has a
high constitutive activity which was reduced by an
inverse agonist for S1P1 (SB649146). A recently
described S1P1 antagonist did not induce lymphopenia
but reversed immunosuppression induced by S1P1
agonist, and furthermore enhanced capillary leakage. A
putative S1P3 receptor antagonist, BML-241, was
identified by searching a three-dimensional compound
database with a pharmacophore model of S1P, however,
BML-241 has appears to have other, GPCR-independent
effects.A specific S1P2 receptor antagonist, JTE-013, has
widely been used to analyse S1P2 signalling pathways.
This compound prevented for example S1P2-mediated
inhibition of cell migration and contraction of smooth
muscle cells. Recently, a series of aryl amide compounds
was presented which were more or less receptor subtype-
selective. The lead compound, VPC23019, was a
competitive antagonist at S1P1 and S1P3. Ki values forVPC23019 in radioligand binding assays at S1P1 and
S1P3 were in the low nanomolar range, and VPC23019
inhibited S1P-induced migration and Ca2+ mobilization.
Small structural changes converted the molecule into an
agonist. Furthermore, VPC23019 as all compounds of
this series behaved as agonist at S1P4 and S1P5, but had
no activity at S1P2. Recently, an anti-S1P antibody was
described. This antibody retarded the proliferation of
various transplanted mouse tumours. Furthermore, it
reduced tumour-associated angiogenesis and the ability
of S1P to protect tumour cells from apoptosis. An
antitumour activity was also observed with SphK
inhibitors.
LPA–GPCR pharmacology is at the experimental
stage.Dioctylglycerol pyrophosphate (DGPP8:0) acts as
a competitive antagonist preferentially at human LPA3
receptors and inhibits at higher concentrations LPA1, but
not LPA2. DGPP 8:0 specifically inhibited LPA-induced
platelet activation. Furthermore, it blocked platelet
activation by mildly oxidized low density lipoproteins
and by homogenates of lipid-rich core isolated from soft
arteriosclerotic plaques, illustrating the importance of
LPA as a component of arteriosclerotic plaques. Fatty
alcohol phosphates (FAP) with carbon chain lengths
between 10 and 14 activate LPA2 and inhibit LPA3 in a
competitive manner. Another LPA–GPCR antagonist is
Ki16425, which was identified by high-throughput
screening of 150,000 compounds for inhibition of
LPA-induced [Ca2+]i increases. This compound inhib-
ited LPA1 andLPA3 at slightly lower concentrations than
LPA2, but was highly specific for LPA-GPCR. A similar
preference for LPA1 and LPA3 was observed with
VPC12249. O-methylphosphothionate (OMPT), a
LPA3-selective agonist, aggravated ischemia-reperfu-
sion injury inmouse kidney,while theLPA1/3 antagonist,
VPC12249, reduced the kidney damage. Since most
compounds that interact with LPA–GPCRs, except
Ki16425, have a phosphate group that can be subject to
dephosphorylation, a novel strategy focuses onmetabol-
ically stabilized LPA analogues such as phosphonates,
phosphorothioates, phosphonothioates and fluoropho-
sphonates. These compounds affect LPA–GPCRs as
well as LPA metabolizing enzymes.
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